



## **CURRICULUM VITAE**

**Naval G. Daver, M.D.**

### **PRESENT TITLE AND AFFILIATION**

#### **Primary Appointment**

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

#### **Dual/Joint/Adjunct Appointment**

N/A

### **CITIZENSHIP**

United States

### **OFFICE ADDRESS**

The University of Texas MD Anderson Cancer Center  
1515 Holcombe Blvd  
FC4.2012  
Unit Number: 428  
Houston, TX 77030  
Phone: (713) 794-4392  
Fax: (713) 794-4297

### **EDUCATION**

#### **Degree-Granting Education**

D.G. Ruparel College, Mumbai, India, BA, 1998, BA

Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, India, MD, 2004, MD

#### **Postgraduate Training**

Research Fellowship, Research Assistant, Baylor College of Medicine, Houston, TX, 9/2004-6/2005

Clinical Residency, Internal Medicine Residency, Baylor College of Medicine, Houston, TX, 7/2005-7/2008

Clinical Fellowship, Fellowship Oncology - Hematology, Baylor College of Medicine, Houston, TX, 7/2008-7/2011

### **CREDENTIALS**

#### **Board Certification**

American Board of Internal Medicine, 12/2008-12/2031

American Board of Oncology, 12/2011-12/2031

American Board of Hematology, 12/2011-12/2031

#### **Licensures**

##### **Active**

Texas Medical Board, TX, P0031, 6/2011-5/2025

##### **Inactive**

N/A

### **EXPERIENCE/SERVICE**

**Academic Appointments**

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2011-8/2017

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2017-present

Director, Department of Leukemia, Leukemia Research Alliance Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2018-present

**Administrative Appointments/Responsibilities**

Advisory Board, HealthTree for AML Community Program, Houston, TX, 8/2022-present

**Other Appointments/Responsibilities**

N/A

**Endowed Positions**

N/A

**Consultantships**

N/A

**Military or Other Governmental Service**

N/A

**Institutional Committee Activities**

MD Anderson Department of Leukemia Fellowship Steering Committee, Co-Leader, 2012-present  
Fellowship Steering Committee, Member, 7/2012-present

MD Anderson Cancer Center BMS -Leukemia Alliance Joint Steering Committee for Leukemia, CO-Chair, 2014-present

Faculty Senate, Senate, 7/2014-present

MD Anderson Cancer Center Immunotherapy platform - BMS Joint Steering Committee, Member, 9/2015-present

MD Anderson Pfizer Alliance, Co-Principal Investigator, 2016-present

MD Anderson Cancer Center CRC 2 Member, Member, 2016-present

Leukemia Research Alliance Program, Director, 5/2018-present

MD Anderson Cancer Center Daiichi Sankyo - Leukemia Alliance Joint Steering Committee for Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Co-Chair, 9/2018-8/2025

**HONORS AND AWARDS**

Distinction in Anatomy and Physiology, Grant Medical College, Mumbai, India, 1999

Distinction in Pathology and Pharmacology, Grant Medical College, Mumbai, India, 2001

Distinction Ophthalmology and ENT, Grant Medical College, Mumbai, India, 2003

Distinction in Medicine and Obstetrics/Gynecology, Grant Medical College, Mumbai, India, 2004

Valedictorian, Class of 2004, Grant Medical College, 2004

Residency Assistance Program, Baylor College of Medicine, 2007-2008

State Medical Jeopardy Winners, Baylor College of Medicine Jeopardy Team, 2007-2008

Leukemia SPORC Career Development Award, SPORC Career Development, 2015-2016

Ladies Leukemia League Grant for AML therapy, 2016-present

Leukemia SPORC Career Development Award, SPORC Career Development, 2016-present

Steering Committee Member, International Working Group Acute Leukemia (iwAL), 2017-present

Frontiers in Oncology, Editorial Board Member, 2019-present  
Blood and Cancer Journal, Editorial Board Member, 2020-present  
Chair, International Working Group Acute Leukemia (iwAL), post ASH Annual Meeting, 2020-present  
Executive Scientific Steering Committee, Karyopharm, Member, 2020-present  
Faculty Educator of the Year, Physicians Education Resource (PER), 2020-2021  
Leukemia and Lymphoma, Editorial Board Member, 2020-present  
SOHO Scientific Committee Steering Committee Member, 2020-present  
Chair, Faron Pharmaceuticals Bexmarililab Steering Committee, 2021-present  
Chair, Novartis Siremadlin Global Clinic Trial Steering Committee, 2021-present  
Co-Chair, Global Leukemia Academy: Emerging and Practical Concepts and Controversies in Leukemias, 2021-present  
Journal of Hematology Oncology, Editorial Board Member, 2021-present  
Chair, AML Clinical Roadmapp, MD Education, 2022  
Chair, Expert Forum on Acute Leukemia and Myelofibrosis, 2022  
Co-Chair, Bermuda Global Summit on Hematologic Malignancies, 2022  
MDACC Faculty Scholar Award FY, 2022

## **RESEARCH**

### **Grants and Contracts**

#### **Funded**

Principal Investigator, 1%, 2014-0861: An Open-label Phase I/II Study of Nivolumab (BMS-936558) in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia, 39923, Bristol-Myers Squibb, 1/23/2015-1/22/2025, \$16,000 (\$20,000/year)

Principal Investigator, 0.12 months, 2017-0855; A phase 1, multicenter, open-label study of IMG632 (CD123 ADC) in patients with relapsed/refractory CD123-positive AML and other CD123-positive hematologic malignancies, Immunogen, 12/1/2017-11/30/2024, \$1,402,400 (\$1,753,000/year)

Co-Investigator, 3%, SPOR in Leukemia Project 5: Targeting Oxidative Phosphorylation in AML, P50 CA100632-16, NIH/NCI, PI - Kantarjian PI/Konopleva Project Leader, 9/1/2018-8/31/2023, \$1,057,220 (\$211,444/year)

Principal Investigator, 0.12 months, 2018-0467; A phase 3 randomized, double-blind trial to evaluate the efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with relapsed/refractory AML, GlycoMimetics, 9/19/2018-2023, \$336,539 (\$420,674/year)

Principal Investigator, 0.12 months, 2018-0675; A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia, Abbvie, 11/15/2018-11/14/2023, \$609,144 (\$761,431/year)

Principal Investigator, 0.12 months, 2018-0608; A Phase Ib/II Study of Venetoclax in Combination with Quizartinib in FLT3-mutated Acute Myelogenous Leukemia (AML), Daiichi Sankyo Co., 11/28/2018-11/27/2023, \$800,000 (\$1,000,000/year)

Principal Investigator, 0.12 months, 2018-0918; A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML), Hanmi Pharm Co, Ltd., 2/5/2019-12/31/2027, \$523,532 (\$654,415/year)

Principal Investigator, 0.12 months, 2017-0795: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Hematological Malignancies, Forty Seven Inc., 7/19/2019-7/18/2026, \$362,050 (\$452,562/year)

Investigator, 0.12 months, 2019-0656: A Phase 1b/2 Study of IMG632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia, ImmunoGen, Inc., PI - Naval Daver, 10/4/2019-10/3/2024, \$329,680 (\$412,100/year)

Principal Investigator, 0.12 months, 2019-0362; A Phase 2/3, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emapalumab in Adult Patients with Hemophagocytic Lymphohistiocytosis, Sobi, 11/26/2019-11/25/2023, \$291,500 (\$233,200/year)

Co-Principal Investigator, Alan and Charlotte Waxman Fund Award, Alan and Charlotte Waxman Fund at Schwab Charitable, PI - Richard Champlin, 12/16/2019-12/15/2026, \$80,000 (\$80,000/year)

Investigator, 0.12 months, 2019-1089: A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML), Newave Pharmaceutical, Inc., PI - Naval Daver, 3/12/2020-3/12/2027, \$533,300 (\$666,625/year)

Principal Investigator, 0.12 months, 2020-0027: Ph1B/2 AZA + VEN + Magrolimab (CD47), Forty Seven Inc., 11/1/2020-2027, \$719,500 (\$899,375/year)

Principal Investigator, 0.12 months, 2021-0007: A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia., Kite Pharma, Inc., 3/19/2021-5/18/2028, \$1,286,500 (\$1,608,125/year)

Principal Investigator, 0.12 months, 2020-0946: An Open-label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination with Azacitidine and Venetoclax or mini-HCVD for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), Daiichi Sankyo Co., LTD, 4/1/2021-4/1/2024, \$2,401,250 (\$3,001,563/year)

Principal Investigator, 0.12 months, 2021-0186: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia, Gilead Sciences, Inc, 4/26/2021-8/25/2028, \$841,897 (\$673,518/year)

Co-Principal Investigator, 1.2 months, Antisense Inhibition of STAT3 in Therapy Resistant Myeloid Malignancies, 1R01CA262893-01, Montefiore Medical Center, PI - Aditi Shastri, 7/1/2021-6/30/2026, \$673,890 (\$134,778/year)

Principal Investigator, 5%, Biology and efficacy of Menin Inhibitors in AML therapy, MDA IRG , 1/1/2022-12/31/2023, \$75,000 (\$75,000/year)

Principal Investigator, 10%, Antisense Inhibition of STAT3 in Therapy Resistant Myeloid Malignancies, FP00015019, Albert Einstein College of Medicine, 7/1/2022-6/30/2027, \$703,523

Collaborator, 15%, Biology and efficacy of Menin Inhibitors in AML therapy., FP00015061, NIH/NCI, PI - Kapil Bhalla, 7/1/2022-6/30/2027, \$1,999,602 (\$399,920/year)

Co-Principal Investigator, 2%, Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML), FP00018527, Break Through Cancer, PI - Jeff Molldrem, 2/28/2023-2/27/2026, \$2,384,348 (\$2,742,000/year)

Co-Investigator, 5%, Focal radiotherapy in stimulate immune responses against systemic leukemias, RP230278, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Michael Spiotto, 3/1/2023-2/28/2026, \$997,500 (\$104,999/year)

Collaborator, 3%, Arming NK Cells to Target B7-H3+ AML Cells, FP00018510/ Grant # TRP-23942-23, Leukemia and Lymphoma Society, PI - Venkata Lokesh Battula, 7/1/2023-6/30/2026, \$681,819 (\$750,000/year)

Co-Investigator, 1%, Targeting Immune-checkpoint protein B7-H3 in Acute Myeloid Leukemia, FP00017673 / Grant # 13723146, Department of Defense Health Program, PI - Venkata Lokesh Battula, 10/1/2023-9/30/2026, \$349,989 (\$566,982/year)

### **Pending**

Principal Investigator, 10%, A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML, FP#17651, NIH, 7/1/2023-6/30/2026, \$577,966 (\$936,305/year)

### **Other**

N/A

### **Completed**

Principal Investigator, 1%, 2012-0737: Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients with Myelofibrosis and Myelodysplastic/ Myeloproliferative Neoplasms, 6410, InCyte, 2/5/2013-2/5/2022, \$1,502,940 (\$1,875,000/year)

Principal Investigator, 1%, 2013-0099: A Phase I/II Study of Vosaroxin and Decitabine in Older Patients with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome, CS2013-37435, Sunesis, 4/16/2013-5/7/2026, \$408,200 (\$81,640/year)

Co-Investigator, 5%, Leukemia SPORE (Project 3: p53 activation as novel therapeutic strategy for acute myelogenous leukemia), 5 P50 CA100632-15, NIH/NCI, PI - Andreeff, 9/13/2013-8/31/2018, \$54,204 (\$54,204/year)

Principal Investigator, 2%, 2014-0975: Phase I/II Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia, 14420, Karyopharm Therapeutics Inc., 9/4/2015-9/3/2018, \$393,673 (\$131,224/year)

Principal Investigator, 2015-1024; A Phase 1, Multi-center, Open-label Study of IMG779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-positive Acute Myeloid Leukemia, ImmunoGen, 3/23/2016-present, \$663,825

Co-Investigator, 0.12 months, First-in-human trial of IACS-010759 in patients with AML, 52852, Leukemia and Lymphoma Society, PI - Draetta, 4/21/2016-4/20/2019, \$3,500,000

Co-Principal Investigator, 1%, Phase 1 Study of IACS-010759 in Subjects with relapsed or refractory AML, Leukemia and Lymphoma Society, PI - Marina Konopleva, 5/1/2016-4/30/2019, \$3,500,000 (\$3,500,000/year)

Collaborator, 5%, Acute Myeloid Leukemia in the Immunosuppressed Microenvironment, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Michael Andreeff, 8/2016-9/1/2021 (\$6,000,000/year)

Principal Investigator, 0.12 months, 2016-0233, A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis, Incyte, 10/17/2016-present, \$547,932

Principal Investigator, 2%, 2016-0444; An Open-label Phase Ib/II Study of Avelumab in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia, Pfizer, 12/8/2016-present (\$812,018/year)

Principal Investigator, 2%, 2016-1130; A Phase 1 study of DS-3201B in subjects with AML and ALL, Daiichi Sankyo, Inc, 3/15/2017-present, \$558,895 (\$558,895/year)

Principal Investigator, 0.24 months, 2016-0782; An Open-Label Phase IB/II Study of Selinexor in combination with Pembrolizumab for the treatment of patients with Refractory/Relapsed Acute Myeloid Leukemia, MDACC, 5/2017-5/2019

Principal Investigator, 2%, 2016-0771; A Phase IB/II Study of Venetoclax (ABT-199) in Combination with Sorafenib in FLT3-mutated Acute Myelogenous Leukemia, Abbvie, 5/2017-4/2020 (\$870,000/year)

Principal Investigator, 2016-0227; Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose Granulocyte-Macrophage Colony Stimulating Factor, As Consolidation Treatment in Patients with Hematologic Malignancies, KiromicPharma, 7/24/2017-present, \$762,589

Principal Investigator, 2017-0259; A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia, Nohla Therapeutics, 11/13/2017-present, \$830,683

Principal Investigator, 0.6 months, 2017-0337: An open-label phase IB multi-arm study of OX40 agonist monoclonal antibody (mAb), anti-4-1BB mAb, anti-PDL1 mAb, smoothed inhibitor, anti-CD33 mAb, and azacitidine as single-agents and/or combinations for the treatment of patients with relapsed or refractory AML, Pfizer, 11/28/2017-11/27/2020, \$1,448,882 (\$1,799,540/year)

Principal Investigator-MDACC, 5%, MDACC-Pfizer Strategic Alliance to evaluate multiple immune checkpoint based therapies in solid tumors, leukemia, multiple myeloma, Pfizer, PI - Daver and Naing, 12/18/2017-12/17/2020, \$13,605,370 (\$465,881/year)

Principal Investigator, 0.12 months, 2017-0900; Phase I, International, multicentre, open-label, non-randomised, non-comparative study of intravenously administered S64315, a Mcl-1 inhibitor, in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS), I.R.I.S. - INSTITUT DE RECHERCHES INTERNATIONALES SERVIER, 2/11/2018-present, \$775,000

Principal Investigator, 0.12 months, 2018-0278; A Phase 1 multicenter study of DS-3032 (MDM2 inhibitor) in combination with quizartinib in subjects with FLT3-ITD mutant AML that are relapsed/refractory, or newly diagnosed and unfit for intensive chemotherapy, Daiichi Sankyo, 6/26/2018-present, \$498,858 (\$623,572/year)

Principal Investigator, 2018-0367; AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATION THE SAFETY AND TOLERABILITY OF DC119718S IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR DC119718S IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED AML UNSUITABLE FOR INTENSIVE INDUCTION CHEMOTHERAPY, Genentech, Inc., 7/2/2018-present, \$907,155

Principal Investigator, 0.12 months, 2018-1007; An International Phase Ib multicentre study to characterize the safety and tolerability of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with orally administered, I.R.I.S, 1/29/2019-1/28/2023, \$336,081 (\$420,101/year)

Principal Investigator, 2019-0100; A Phase IB/II Study Evaluating The Safety And Efficacy Of Idasanutlin In Combination With Cytarabine And Daunorubicin In Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) And The Safety And Efficacy Of Idasanutlin In The Maintenance Of First AML Complete Remission, F. Hoffman La Roche Ltd, 7/22/2019-7/21/2026

Investigator, 0.12 months, 2019-0688: A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezoliumab (Anti-PD-L1 Antibody) Administered in Combination with Hu5F9-G4 to Patients with Relapsed and/or Refractory Acute Myeloid Leukemia, 2019-0688: A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezoliumab (Anti-PD-L1 Antibody) Administered in Combination with Hu5F9-G4 to Patients

with Relapsed and/or Refractory Acute Myeloid Leukemia, Genentech, Inc, 10/23/2019-10/22/2027, \$361,601

Principal Investigator, 0.12 months, Simultaneous targeting of mutant FLT3-pathways and anti-apoptotic BCL-2 signaling in AML, RCTS#58081, IRG MDACC, 3/9/2020-3/8/2021, \$75,000 (\$37,500/year)

Principal Investigator, 0.12 months, 2021-0099: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies, Gilead Sciences, Inc, 5/7/2021, \$885,860 (\$1,107,325/year)

#### **Not Funded**

Principal Investigator, 10%, Simultaneous targeting of mutant FLT3 pathways and anti-apoptotic BCL-2 signaling in AML, NIH R21, 7/2017-6/2019, \$250,000 (\$125,000/year)

Co-Principal Investigator, 2%, Preclinical Testing of Galectin-3C, NIH STTR Fast-Track, 7/1/2017-6/30/2019 (\$3,444,095/year)

Co-Principal Investigator, 3%, Targeting Metabolic Vulnerability of AML LSC with Novel Inhibitor of Oxidative Phosphorylation, NIH/NCI, PI - Marina Konopleva, 7/2017-6/2020 (\$200,000/year)

Co-Principal Investigator, 10%, iREACT: Immune Related Adverse Events Induced by Checkpoint Therapy: MDACC Efforts for Advanced Mechanistic, Clinical, and Translational Science, Cancer Prevention & Research Institute of Texas (CPRIT), 8/31/2018-8/30/2022, \$609,984 (\$146,850/year)

Co-Investigator, 0.12 months, Investigating Novel therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy: the INTERCEPT study, FP00009733\_Res1, Leukemia and Lymphoma Society, PI - Andrew Wei, 10/1/2021-9/30/2024, \$224,987 (\$74,996/year)

#### **Protocols**

##### **Funded**

Principal Investigator, A Phase I/II Study of Vosaroxin and Decitabine in Older Patients with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,, 2013-0099, 2013-2020, \$408,200 (\$81,640/year), Sunesis

Principal Investigator, Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients with Myelofibrosis and Myelodysplastic/ Myeloproliferative Neoplasms,, 2012-0737, 2013-2024, \$1,875,000, Incyte

Principal Investigator, Open-Label, Phase I/II Study of Nilotinib (Tasigna) + MEK-162 (ARRY-162) for Patients with Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia, 2014-0128, 2014-2017, \$902,003 (\$300,668/year), Novartis

Principal Investigator, An Open-label Phase II Study of Lirilumab (BMS-986015) in Combination with 5-azacytidine (vidaza) for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia, 2014-0862, 2014-2018, BMS Pharmaceuticals

Principal Investigator, Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia, 2014-0975, 2014-2019, Karyopharm

Principal Investigator, Phase II, Dose-Escalation Study of Ponatinib, a FLT3 inhibitor, with and without combination of 5-Azacytidine, in patients with FLT3-mutated Acute Myeloid Leukemia (AML), 2014-1083, 2014-present, Ariad

Principal Investigator, An Open-label Phase II Study of Nivolumab (BMS-936558) in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia, 2014-0861, 2015-present, \$20,000, BMS Pharmaceuticals

Principal Investigator, A Phase Ib/II Study of venetoclax (ABT-199) in Combination with Sorafenib in FLT3-mutated Acute Myelogenous Leukemia, 2016-0771, 2016-2017, Abbvie

Principal Investigator, An Open-Label Phase IB/II Study of Selinexor in Combination with Pembrolizumab for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia, 2016-0782, 2016-2018, Karyopharm/Merck

Principal Investigator, Phase I/II MultiCenter Study of KV-001 Dendritic Cell Vaccine for Consolidation Therapy in Patients with Leukemias (AML, CLL, CML, ALL) Following Response to Standard Therapy, 2016-0227, 2016-2019, Kiromic

Principal Investigator, A Phase 1, Multi-center, Open-label Study of IMG779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-positive Acute Myeloid Leukemia, 2015-1024, 2016-2020, \$663,825, ImmunoGen

Principal Investigator, An Open-label Phase IB/II Study of Avelumab in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia, 2016-0444, 2016-2020, Pfizer

Principal Investigator, A Phase I Study of DS-3201B in Subjects with Acute Myelogenous Leukemia (AML), 2016-1130, 2016-2022, \$673,916, Daiichi Sankyo, Inc.

Principal Investigator, A Phase 2 MultiCenter Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis, 2016-0233, 2016-present, \$676,450, Incyte

Principal Investigator, An Observational, multicenter study to evaluate interferon gamma (IFN $\gamma$ ) and other inflammatory mediators in patients with malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH), PA16-0129, 2016-present, \$45,500, Novimmune

Principal Investigator, A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia, 2017-0259, 2017-2019, NOHLA Therapeutics

Principal Investigator, An Open-label Phase IB/II Multi-arm Study of OX40 agonist monoclonal antibody (mAb), anti-41BB mAb, anti-PDL1 mAb, smoothed inhibitor, anti-CD33 mAb, and azacitidine as single-agents and/or combinations for the Treatment of Patients with Acute Myeloid Leukemia (AML), 2017-0337, 2017-2022, \$1,799,540, Pfizer Alliance

Co-Principal Investigator, A Phase 1, Multi-center, Open-label Study of IMG632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies, 2017-0855, PI - Hagop Kantarjian, 2017-present, \$1,753,000, ImmunoGen, Inc.

Principal Investigator, A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis, 2016-0233, 2017-present, \$676,450,000, Incyte

Principal Investigator, An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination with Azacitidine in Patients with Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy, 2018-0367, 2018-2020, Genentech

Co-Principal Investigator, A Phase II Study of Quizartinib in Combination with Decitabine for the Treatment of Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS), 2018-0394, 2018, \$1,300,000, Daiichi Sankyo Co., LTD.

Principal Investigator, A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezoliumab (Anti-PD-L1 Antibody) Administered in Combination with Hu5F9-G4 to Patients with Relapsed and/or Refractory Acute Myeloid Leukemia, 2019-0688, 2019-2021, \$361,601, Genentech, Inc

Principal Investigator, ASP2215 (Gilteritinib) + Atezolizumab in R/R FLT3+ AML, 2018-0930, PI - Daver,Naval, 2019-2021, \$147,352, Astellas Pharma US, Inc.



Principal Investigator, A Phase 2/3, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emapalumab in Adult Patients with Hemophagocytic Lymphohistiocytosis, 2019-0362, 2019-2022, \$291,500, Sobi

Principal Investigator, A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia, 2019-0656, 2019-2026, \$412,100, ImmunoGen, Inc

Principal Investigator, 2018-0918, 2018-0918, 2019-present, \$706,003, Aptose Biosciences

Principal Investigator, An International Phase Ib multicentre study to characterize the safety and tolerability of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with orally administered, 2018-1007, 2019-present, \$420,101, I.R.I.S

Principal Investigator, A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML), 2019-1089, 2020-2027, \$666,625, Newave Pharmaceutical

Principal Investigator, An Open-label Phase IB/II Study of Magrolimab in Combination with Azacitidine and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia (AML), 2020-0027, 2020-2027, \$422,500, Genentech Inc.

Co-Principal Investigator, Ph1 FT516 (NK cells) in R/R AML, 2019-0615, PI - Strati,Paolo, 2020, \$375,982, Fate Therapeutics

Principal Investigator, A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy, 2021-0790, 2021-2028, \$379,375, Gilead Sciences Inc.

Principal Investigator, A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia., 2021-0007, 2021-present, \$1,608,125, Kite Pharma, Inc

Principal Investigator, A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies, 2021-0099, 2021-present, \$1,107,325, Gilead Sciences, Inc.

Principal Investigator, A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia, 2021-0186, 2021-present, \$841,897, Gilead Sciences, Inc.

Principal Investigator, An Open-label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination with Azacitidine and Venetoclax or mini-HCVD for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), 2020-0946, 2021-present, \$3,001,563, Daiichi Sankyo Co., LTD.

Principal Investigator, An Open-Label Phase IB Study Of DSP107OR Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), 2021-0654, 2021-present, \$1,343,979, KAHR Medical

Co-Principal Investigator, Ph1a/1b TTI-622 + Azacitidine in AML /CMML OR TTI-662 + Azacitidine + Venetoclax in AML, 2018-1064, PI - Iyer,Swaminathan P., 2021-present, \$1,356,875, Trillium Therapeutics Inc.

Principal Investigator, A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination with Venetoclax and/or Azacitidine in Subjects with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome, 2021-0503, 2021, \$824,225, Abbvie

Principal Investigator, Ph1 FT538 in relapsed/refractory AML, 2021-0414, PI - Daver, Naval, 2021, \$532,045, Fate Therapeutics

Principal Investigator, Phase 1a/1b Study of SL-172154 in Subjects with Higher-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia, 2022-0038, 2022-2029, \$1,826,215, Shattuck Labs

Principal Investigator, A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination with Antineoplastic Agents in Subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes, 2021-1046, 2022-present, Bristol-Myers Squibb

Principal Investigator, A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation, 2021-0711, 2022-present, \$868,675, Sumitomo Dainippon Pharma Oncology Inc.

Principal Investigator, A phase Ib, multicenter study of VOB560 in combination with MIK665 in patients with relapsed/refractory non- Hodgkin lymphoma, relapsed/refractory acute myeloid leukemia, or relapsed/refractory multiple myeloma, 2021-0220, 2022, \$590,625, Novartis

Principal Investigator, A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML subjects who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in subjects with newly diagnosed unfit AML presenting with high-risk clinical features, 2021-1181, 2022, \$1,045,131, Novartis

Principal Investigator, Title AN OPEN-LABEL, MULTI-CENTER, PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7283420 AS A SINGLE AGENT IN HEMATOLOGIC AND MOLECULAR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA, 2021-0808, 2022, \$462,465, Genentech, Inc.

Principal Investigator, A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy (VICEROY), 2022-0036, 2023

Principal Investigator, A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy (VICEROY), 2022-0036, 2023, \$559,550, Astellas Pharma Global Development, Inc. (APGD)

#### **Unfunded**

Principal Investigator, Alemtuzumab in Combination with Etoposide and Dexamethasone for the Treatment of Adult Patients with Hemophagocytic Lymphohistiocytosis, 2014-0989, 2014-present

Principal Investigator, An Open-label Phase II Study of Lorvotuzumab mertansine (IMGN901) in CD56 expressing hematological malignancies, 2014-0926, 2014-present, Immunogen

Principal Investigator, Changes in Gene Expression to Predict Responses to Immunotherapy in Leukemia, PA17-0102, 2016-present

Principal Investigator, A Phase 1 Study of DS-3032B in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia that are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy, 2018-0278, 2018-present, \$623,572, Daiichi Sankyo, Inc.

Principal Investigator, A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia, 2018-0467, 2018-present, \$420,674, GlycoMimetics, Inc.

Principal Investigator, A phase Ib, multicenter study of VOB560 in combination with MIK665 in patients with relapsed/refractory non-Hodgkin lymphoma, relapsed/refractory acute myeloid leukemia, or relapsed/refractory multiple myeloma, 2021-0220, 2021-present, Novartis

Principal Investigator, Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with azacitidine in patients with acute myeloid leukaemia (AML), 2021-0048, 2021-present, \$1,854,630, I.R.I.S. INSTITU DE RECHERCHES INTERNATIONALES SERVIER

## Patents and Technology Licenses

### Patents

N/A

### Technology Licenses

N/A

## Grant Reviewer/Service on Study Sections

N/A

## PUBLICATIONS

### Peer-Reviewed Original Research Articles

1. Joshi SR, Butala N, Patwardhan MR, **Daver NG**, Kelkar D. Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. *J Assoc Physicians India* 52(1):597- 598, 7/2004. PMID: 15645995.
2. Daver GB, Bakhshi GD, Patil A, Ellur S, Jain M, **Daver N**. Bifid liver in a patient with diaphragmatic hernia. *Indian J Gastroenterol* 24(1):27-8, Jan-Feb, 1/2005. PMID: 15778526.
3. del la Garza Y, Graviss EA, **Daver NG**, Gambarin KJ, Shandera WX, Schantz PM, White AC. Epidemiology of neurocysticercosis in Houston, Texas. *American Journal Tropical Medicine and Hygiene* 73(4):766-70, 10/2005. PMID: 16222023.
4. **Daver NG**, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC. Oral step-down therapy is comparable to intravenous therapy for *Staphylococcus aureus* osteomyelitis. *The Journal of Infection* 54(6):539-44, 6/2007. e-Pub 1/2007. PMID: 17198732.
5. Livorsi DJ, **Daver NG**, Atmar RL, Shelburne SA, White AC, Musher DM. Outcomes of treatment for hematogenous *Staphylococcus aureus* vertebral osteomyelitis in the MRSA ERA. *J Infect* 57(2):128-31, 8/2008. e-Pub 6/2008. PMID: 18562009.
6. Tanaka MF, **Daver NG**, Rice L. Romiplostim: Therapeutic Value in Chronic Immune Thrombocytopenic Purpura. *Clinical Medical Insights: Therapeutics*(2):499-511, 5/2010.
7. Shastri A, **Daver NG**, Hayes TG. Primary gastric chorioadenocarcinoma: a needle in a haystack. *Rare Tumors* 3(2):e19, 4/2011. PMCID: PMC3132123.
8. Nazha A, Cortes J, Faderl S, Pierce S, **Daver NG**, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. *Haematologica* 97(8):1242-5, 8/2012. e-Pub 4/2012. PMCID: PMC3409823.
9. **Daver NG**, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. *Am J Hematol* 88(1):56-9, 1/2013. e-Pub 10/2012. PMCID: PMC4085099.
10. Lee HJ, **Daver NG**, Kantarjian HM, Verstovsek S, Ravandi F. The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. *Clin Cancer Res* 19(2):327-35, 1/2013. e-Pub 12/2012. PMID: 23209034.
11. Borthakur G, Rosenblum MG, Talpaz M, **Daver NG**, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 Study of Anti-CD33 Immunotoxin HUM-195/rGEL in Patients with Advanced Myeloid Malignancies. *Haematologica* 98(2):217-21, 2/2013. e-Pub 8/2012. PMCID: PMC3561428.

12. **Daver NG**, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: Are purine analogues and rituximab viable therapeutic options. *Clin Lymphoma Myeloma Leuk* 13(1):86-9, 2/2013. e-Pub 9/2012. PMID: PMC4084644.
13. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, **Daver NG**, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. *Am J Hematol* 88(3):198-200, 3/2013. e-Pub 1/2013. PMID: PMC4085133.
14. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, **Daver NG**, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. *Leukemia* 27(4):836-42, 4/2013. e-Pub 11/2012. PMID: PMC4181539.
15. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, **Daver NG**. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. *Clin Lymphoma Myeloma Leuk* 13(3):342-6, 6/2013. e-Pub 12/2012. PMID: PMC4019340.
16. **Daver NG**, O'Brien S. Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia - A Focus on Emerging Monoclonal Antibodies. *Curr Hematol Malig Rep* 8(2):123-31, 6/2013. e-Pub 3/2013. PMID: PMC4438701.
17. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, **Daver NG**, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood* 121(23):4655-62, 6/2013. e-Pub 4/2013. PMID: PMC3674666.
18. **Daver NG**, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. *Clin Lymphoma Myeloma Leuk* 13(4):435-40, 8/2013. e-Pub 6/2013. PMID: PMC4114766.
19. **Daver NG**, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II Open-label Study of the Intravenous Administration of Homoharringtonine in the treatment of Myelodysplastic syndrome. *Eur J Cancer Care (Engl)* 22(5):605-11, 9/2013. e-Pub 5/2013. PMID: PMC3745781.
20. Strati P, **Daver NG**, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 13 Suppl 2:S276-81, 9/2013. e-Pub 8/2013. PMID: PMC4101888.
21. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, **Daver NG**, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. *Leukemia* 27(10):2081-3, 10/2013. e-Pub 6/2013. PMID: 23774633.
22. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, **Daver NG**, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. *Am J Hematol* 88(11):961-6, 11/2013. e-Pub 9/2013. PMID: PMC4110914.
23. **Daver NG**, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. *Leuk Res* 37(11):1440-4, 11/2013. e-Pub 7/2013. PMID: PMC4232180.
24. Jabbour E, **Daver NG**, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients

- with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. *Am J Hematol* 89(4):395-8, 4/2014. e-Pub 3/2014. PMID: PMC4140180.
25. DiNardo CD, **Daver NG**, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. *Leukemia* 28(4):958-61, 4/2014. e-Pub 1/2014. PMID: PMC3981947.
  26. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, **Daver NG**, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplastic syndrome and chronic myelomonocytic leukemia post clofarabine failure. *Ther Adv Hematol* 5(2):29-34, 4/2014. PMID: PMC3949300.
  27. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, **Daver NG**, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. *Clin Lymphoma Myeloma Leuk* 14(2):163-71, 4/2014. e-Pub 1/2014. PMID: PMC4167660.
  28. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, **Daver NG**, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. *Leukemia* 28(4):973-5, 4/2014. e-Pub 10/2013. PMID: 24157581.
  29. **Daver NG**, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. *Am J Hematol* 89(5):509-16, 5/2014. e-Pub 2/2014. PMID: PMC4221257.
  30. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, **Daver NG**, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. *Leuk Lymphoma* 55(6):1337-44, 6/2014. e-Pub 10/2013. PMID: PMC4143910.
  31. Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, **Daver NG**. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. *Clin Lymphoma Myeloma Leuk* 14(4):e115-8, 8/2014. e-Pub 2/2014. PMID: PMC4403758.
  32. Shah DR, **Daver NG**, Borthakur G, Hirsch-Ginsberg C, Oo TH. Pernicious anemia with spuriously normal vitamin B12 level might be misdiagnosed as myelodysplastic syndrome. *Clin Lymphoma Myeloma Leuk* 14(4):e141-3, 8/2014. e-Pub 2/2014. PMID: 24630920.
  33. **Daver NG**, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. *Leuk Res* 38(9):1126-9, 9/2014. e-Pub 7/2014. PMID: PMC4157096.
  34. Quintas-Cardama A, **Daver NG**, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 14(5):401-10, 10/2014. e-Pub 5/2014. PMID: PMC4167474.
  35. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, **Daver NG**, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. *Leuk Res* 38(10):1212-6, 10/2014. e-Pub 8/2014. PMID: PMC4182146.
  36. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, **Daver NG**, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). *Cancer* 120(23):3660-8, 12/2014. e-Pub 7/2014. PMID: PMC4239168.
  37. Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, **Daver NG**, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures,

- kidney failure, and liver cirrhosis treated with single-agent cladribine. *Front Oncol* 4:297, 2014. e-Pub 10/2014. PMID: PMC4212618.
38. Pemmaraju N, Chang E, **Daver NG**, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. *Front Oncol* 4:130, 2014. e-Pub 6/2014. PMID: PMC4040935.
  39. DiNardo CD, **Daver NG**, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. *Lancet Haematol* 2(1):e12-20, 1/2015. e-Pub 12/2014. PMID: PMC4936479.
  40. **Daver NG**, Cortes J. The changing face of acute myeloid leukemia therapeutics in the elderly population. *South Asian J Cancer* 4(1):1-2, Jan-Mar, 1/2015. PMID: PMC4382773.
  41. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, **Daver NG**, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 15(2):110-4, 2/2015. e-Pub 7/2014. PMID: PMC4294996.
  42. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, **Daver NG**, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. *Am J Hematol* 90(2):120-4, 2/2015. e-Pub 11/2014. PMID: PMC4447180.
  43. **Daver NG**, Verstovsek S. Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. *Leuk Lymphoma* 56(2):279-80, 2/2015. e-Pub 7/2014. PMID: 24913500.
  44. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, **Daver NG**, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. *Leuk Lymphoma* 56(2):390-4, 2/2015. e-Pub 7/2014. PMID: PMC4297591.
  45. **Daver NG**, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. *Br J Haematol* 168(5):646-53, 3/2015. e-Pub 10/2014. PMID: PMC4323735.
  46. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, **Daver NG**, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. *Cancer* 121(6):876-82, 3/2015. e-Pub 11/2014. PMID: PMC4378905.
  47. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, **Daver NG**, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. *J Neurooncol* 122(2):391-8, 4/2015. e-Pub 2/2015. PMID: PMC4369460.
  48. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, **Daver NG**, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *Am J Hematol* 90(4):276-81, 4/2015. e-Pub 3/2015. PMID: PMC4376596.
  49. **Daver NG**, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. *Haematologica* 100(5):653-61, 5/2015. e-Pub 2/2015. PMID: PMC4420214.

50. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, **Daver NG**, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. *Leuk Lymphoma* 56(5):1-4, 5/2015. e-Pub 11/2014. PMID: PMC4417657.
51. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, **Daver NG**, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. *Lancet Haematol* 2(5):e186-93, 5/2015. e-Pub 4/2015. PMID: PMC4884053.
52. **Daver NG**, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. *Blood* 125(21):3236-45, 5/2015. e-Pub 3/2015. PMID: PMC4440880.
53. **Daver NG**, Bumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia. *Clin Cancer Res* 21(12):2704-14, 6/2015. e-Pub 2/2015. PMID: PMC4470787.
54. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, **Daver NG**, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 15(6):358-63, 6/2015. e-Pub 12/2014. PMID: PMC4457594.
55. Ouyang J, Goswami M, Tang G, Peng J, Ravandi F, **Daver NG**, Routbort M, Konoplev S, Lin P, Medeiros LJ, Jorgensen JL, Wang SA. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. *Am J Hematol* 90(6):504-10, 6/2015. e-Pub 4/2015. PMID: 25732229.
56. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, **Daver NG**, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. *Leukemia*. e-Pub 7/2015. PMID: 26228814.
57. Gowin K, Verstovsek S, **Daver NG**, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. *Leuk Res* 39(7):684-8, 7/2015. e-Pub 4/2015. PMID: 25922307.
58. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, **Daver NG**, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. *Haematologica* 100(7):927-34, 7/2015. e-Pub 2/2015. PMID: PMC4486227.
59. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, **Daver NG**, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. *Br J Haematol* 170(4):590-3, 8/2015. e-Pub 2/2015. PMID: 25716073.
60. **Daver NG**, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. *Haematologica* 100(8):1058-63, 8/2015. e-Pub 6/2015. PMID: 26088933.
61. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, **Daver NG**, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. *Am J Hematol* 90(9):769-73, 9/2015. e-Pub 7/2015. PMID: PMC4546505.
62. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, **Daver NG**, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line

- treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. *Lancet Haematol* 2(9):e376-e383, 9/2015. PMID: PMC4587395.
63. Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, **Daver NG**, Chung W, Naim S, Taverna P, Oganessian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. *Lancet Oncol* 16(9):1099-110, 9/2015. e-Pub 8/2015. PMID: 26296954.
  64. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, **Daver NG**, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. *Leuk Res* 39(9):950-6, 9/2015. e-Pub 6/2015. PMID: PMC4546869.
  65. Nazha A, Houry JD, Rampal RK, **Daver NG**. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. *Oncologist* 20(10):1154-60, 10/2015. e-Pub 8/2015. PMID: PMC4591957.
  66. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, **Daver NG**, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Houry JD, Jorgensen J, Estrov Z, Bohannon Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. *Lancet Oncol* 16(15):1547-55, 11/2015. e-Pub 9/2015. PMID: 26432046.
  67. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, **Daver NG**, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. *Am J Hematol* 90(11):1065-70, 11/2015. e-Pub 9/2015. PMID: PMC4618182.
  68. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannon Z, Pierce S, Jabbour EJ, Ravandi F, **Daver NG**, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. *Leuk Res* 39(12):1367-74, 12/2015. e-Pub 10/2015. PMID: 26547258.
  69. **Daver NG**, Konopleva M. Sorafenib and novel multikinase inhibitors in AML. *Lancet Oncol* 16(16):1582-3, 12/2015. e-Pub 11/2015. PMID: 26549588.
  70. Pemmaraju N, Sasaki K, Johnson D, **Daver NG**, Afshar-Kharghan V, Chen M, Ahmed S, Colen RR, Kwon M, Huh Y, Borthakur G. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. *Front Oncol* 5:29, 2015. e-Pub 2/2015. PMID: PMC4324079.
  71. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, **Daver NG**, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. *Cancer* 122(2):238-48, 1/2016. e-Pub 10/2015. PMID: PMC4707980.
  72. **Daver NG**, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. *Leukemia* 30(2):268-73, 2/2016. e-Pub 9/2015. PMID: 26365212.
  73. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreeff M, Konopleva M, DiNardo C, **Daver NG**, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. *Oncotarget* 7(12):14172-87, 3/2016. e-Pub 2/2016. PMID: PMC4924706.
  74. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, **Daver NG**, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of



- Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. *Clin Lymphoma Myeloma Leuk* 16(3):152-62, 3/2016. e-Pub 12/2015. PMID: PMC4769134.
75. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, **Daver NG**, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Blood* 127(10):1269-75, 3/2016. e-Pub 1/2016. PMID: PMC4786836.
  76. Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, **Daver NG**, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. *Am J Hematol* 91(3):354-5, 3/2016. e-Pub 1/2016. PMID: PMC4764477.
  77. **Daver NG**, Cortes J, Kantarjian H, Ravandi F. Acute myeloid leukemia: advancing clinical trials and promising therapeutics. *Expert Rev Hematol* 9(5):433-45, 5/2016. e-Pub 3/2016. PMID: PMC5006674.
  78. Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, **Daver NG**, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. *Am J Hematol* 91(4):E274-6, 6/2016. e-Pub 2/2016. PMID: 26798971.
  79. Ouyang J, Goswami M, Peng J, Zuo Z, **Daver NG**, Borthakur G, Tang G, Medeiros LJ, Jorgensen JL, Ravandi F, Wang SA. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. *Am J Clin Pathol* 145(6):769-77, 6/2016. e-Pub 6/2016. PMID: 27298396.
  80. **Daver NG**, Ravandi F. Enhancing cytotoxicity of immunotoxins in AML. *Blood* 127(23):2787-8, 6/2016. PMID: 27282944.
  81. Jain P, Tang G, Huh YO, Yin CC, Zuo Z, Pemmaraju N, Estrov Z, **Daver NG**. Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. *Am J Hematol* 91(6):647-8, 6/2016. e-Pub 2/2016. PMID: PMC4870100.
  82. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, **Daver NG**, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. *Am J Hematol* 91(4):385-9, 6/2016. e-Pub 2/2016. PMID: 26800008.
  83. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, **Daver NG**, Chemaly RF, Marsh L, Ghantaji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. *Cancer* 122(14):2186-96, 7/2016. e-Pub 5/2016. PMID: 27142181.
  84. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, **Daver NG**, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. *Cancer*. e-Pub 7/2016. PMID: 27463065.
  85. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, **Daver NG**, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-münster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen. *Am J Hematol* 91(8):819-23, 8/2016. e-Pub 6/2016. PMID: 27178680.
  86. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, **Daver NG**, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. *Haematologica* 101(8):e324-7, 8/2016. e-Pub 5/2016. PMID: PMC4967581.

87. **Daver NG**, Konopleva M. Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL. *Blood* 128(10):1316-7, 9/2016. PMID: 27609539.
88. Tamamyian GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, **Daver NG**. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. *Cancer* 122(18):2857-66, 9/2016. e-Pub 5/2016. PMID: PMC5014667.
89. Khan M, Sarfraz M, **Daver NG**. Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition. *Future Oncol.* e-Pub 9/2016. PMID: 27676208.
90. Nazha A, Houry JD, Verstovsek S, **Daver NG**. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure? *Crit Rev Oncol Hematol* 105:112-7, 9/2016. e-Pub 6/2016. PMID: 27401783.
91. Alatrash G, **Daver NG**, Mittendorf EA. Targeting Immune Checkpoints in Hematologic Malignancies. *Pharmacol Rev* 68(4):1014-1025, 10/2016. PMID: 27664133.
92. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, **Daver NG**, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. *Cancer* 122(21):3336-3343, 11/2016. e-Pub 8/2016. PMID: PMC5073019.
93. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, **Daver NG**, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. *Clin Lymphoma Myeloma Leuk* 16(11):616-624, 11/2016. e-Pub 8/2016. PMID: PMC5408349.
94. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, **Daver NG**, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 122(23):3650-3656, 12/2016. e-Pub 8/2016. PMID: PMC5321539.
95. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, **Daver NG**. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. *Am J Hematol* 92(1):7-11, 1/2017. e-Pub 12/2016. PMID: PMC5361214.
96. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, **Daver NG**, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. *Genome Med* 9(1):21, 2/2017. e-Pub 2/2017. PMID: PMC5331640.
97. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, **Naval Daver**, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. *Am J Hematol* 92(2):155-160, 2/2017. e-Pub 11/2016. PMID: PMC5338569.
98. Tamamyian G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, **Daver NG**, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. *Crit Rev Oncol Hematol* 110:20-34, 2/2017. e-Pub 12/2016. PMID: 28109402.
99. **Daver NG**, Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. *Lancet Oncol* 18(2):169-171, 2/2017. PMID: 28214404.
100. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, **Daver NG**, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. *Cancer* 123(3):426-435, 2/2017. e-Pub 9/2016. PMID: PMC5258784.
101. Jabbour E, Faderl S, Sasaki K, Kadia T, **Daver NG**, Pemmaraju N, Patel K, Houry JD, Bueso-Ramos C, Bohannon Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus

- cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. *Cancer* 123(4):629-637, 2/2017. e-Pub 10/2016. PMID: 27741352.
102. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, **Daver NG**, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. *Cancer* 123(3):459-467, 2/2017. e-Pub 10/2016. PMCID: PMC5321542.
  103. Assi R, Verstovsek S, **Naval Daver**. 'Janus kinase-ing' up the treatment of primary myelofibrosis: building better combination strategies. *Curr Opin Hematol* 24(2):115-124, 3/2017. e-Pub 1/2017. PMID: 28072602.
  104. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, **Daver NG**, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. *Blood* 129(10):1275-1283, 3/2017. e-Pub 12/2016. PMCID: PMC5413297.
  105. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, **Daver NG**, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. *Am J Hematol* 92(3):238-243, 3/2017. e-Pub 2/2017. PMCID: PMC5495018.
  106. Naqvi K, **Daver NG**, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. *Leuk Lymphoma* 58(4):1-6, 4/2017. e-Pub 8/2016. PMCID: PMC5521009.
  107. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, DiNardo C, **Daver NG**, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. *Am J Hematol* 92(4):351-358, 4/2017. e-Pub 2/2017. PMCID: PMC5439522.
  108. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, **Daver NG**, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. *Am J Hematol* 92(4):331-337, 4/2017. e-Pub 2/2017. PMCID: PMC5352512.
  109. Jabbour E, **Daver NG**, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. *Am J Hematol*. e-Pub 5/2017. PMID: 28556489.
  110. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, **Daver NG**, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. *Blood* 129(18):2584-2587, 5/2017. e-Pub 2/2017. PMCID: PMC5418636.
  111. Hust MA, Blechacz BRA, Bonilla DL, **Daver NG**, Rojas-Hernandez CM. Adult cancer-related hemophagocytic lymphohistiocytosis - a challenging diagnosis: a case report. *J Med Case Rep* 11(1):172, 6/2017. e-Pub 6/2017. PMCID: PMC5485603.
  112. Strati P, Masarova L, Bose P, **Naval Daver**, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. *Leuk Res* 57:85-88, 6/2017. e-Pub 3/2017. PMID: 28324773.

113. Shah AR, Muzzafar T, Assi R, Schellingerhout D, Estrov Z, Tamamyian G, Kantarjian H, **Daver NG**. Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. *BBA Clin* 7:36-40, 6/2017. e-Pub 12/2016. PMID: 28070498.
114. Otrrock ZK, **Daver NG**, Kantarjian HM, Eby CS. Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. *Clin Lymphoma Myeloma Leuk* 17S:S105-S110, 7/2017. PMID: 28760295.
115. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, **Daver NG**, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. *Blood Adv* 1(17):1312-1323, 7/2017. e-Pub 7/2017. PMCID: PMC5727976.
116. Newberry KJ, Patel K, Masarova L, Luthra R, Manshoury T, Jabbour E, Bose P, **Daver NG**, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood* 130(9):1125-1131, 8/2017. e-Pub 7/2017. PMCID: PMC5580275.
117. Boddu P, Kantarjian H, Borthakur G, Kadia T, **Daver NG**, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. *Blood Adv* 1(19):1546-1550, 8/2017. e-Pub 8/2017. PMCID: PMC5728474.
118. **Daver NG**, Kantarjian H. FLT3 inhibition in acute myeloid leukaemia. *Lancet Oncol* 18(8):988-989, 8/2017. e-Pub 7/2017. PMID: 28759368.
119. Masarova L, Bose P, **Naval Daver**, Pemmaraju N, Newberry KJ, Manshoury T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. *Leuk Res* 59:110-116, 8/2017. e-Pub 6/2017. PMCID: PMC5573611.
120. **Daver NG**, McClain K, Allen CE, Parikh SA, Otrrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, La Rosée P, Kantarjian HM. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. *Cancer* 123(17):3229-3240, 9/2017. e-Pub 6/2017. PMCID: PMC5568927.
121. Mirandola L, Pedretti E, Figueroa JA, Chiamonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, **Daver NG**, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. *Oncotarget* 8(43):74378-74390, 9/2017. e-Pub 8/2017. PMCID: PMC5650349.
122. Ragon BK, **Daver NG**, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia. *Am J Hematol* 92(9):845-850, 9/2017. e-Pub 6/2017. PMID: 28494506.
123. Masarova L, Verstovsek S, Kantarjian H, **Daver NG**. Immunotherapy based approaches in myelofibrosis. *Expert Rev Hematol* 10(10):903-914, 10/2017. e-Pub 8/2017. PMID: 28799436.
124. **Daver NG**, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Noguera González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. *Haematologica* 102(10):1709-1717, 10/2017. e-Pub 7/2017. PMCID: PMC5622855.
125. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, **Daver NG**, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. *Cancer* 123(22):4430-4439, 11/2017. e-Pub 7/2017. PMID: 28708931.
126. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Noguera Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, **Daver NG**, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F,

- Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. *Cancer* 123(22):4391-4402, 11/2017. e-Pub 7/2017. PMID: PMC5673547.
127. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, **Naval Daver**, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype. *Eur J Haematol* 99(6):536-543, 12/2017. e-Pub 10/2017. PMID: 28926144.
  128. **Daver NG** Kontoyiannis DP. Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. *Lancet Oncol* 18(12):1571-1573, 12/2017. PMID: 29208429.
  129. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, **Daver NG**, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. *Am J Hematol* 92(12):1295-1302, 12/2017. e-Pub 9/2017. PMID: 28850699.
  130. Jain N, Lu X, **Daver NG**, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. *Haematologica* 102(12):e514-e517, 12/2017. e-Pub 8/2017. PMID: PMC5709127.
  131. Assi R, Kantarjian H, Short NJ, **Daver NG**, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. *Clin Lymphoma Myeloma Leuk* 17(12):897-901, 12/2017. e-Pub 8/2017. PMID: 28927784.
  132. Masarova L, Kantarjian H, Garcia-Manero G, Ravandi F, Sharma P, **Daver NG**. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. *Adv Exp Med Biol* 995:73-95, 2017. PMID: 28321813.
  133. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, **Daver NG**, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat Rev Clin Oncol* 15(1):47-62, 1/2018. e-Pub 9/2017. PMID: 28925994.
  134. Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, **Daver NG**, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. *Cancer* 124(2):325-334, 1/2018. e-Pub 12/2017. PMID: PMC5814873.
  135. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, **Daver NG**, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. *Am J Hematol* 93(1):91-99, 1/2018. e-Pub 11/2017. PMID: 29047158.
  136. Alhurajji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, **Daver NG**, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. *Am J Hematol* 93(1):84-90, 1/2018. e-Pub 11/2017. PMID: 29027261.
  137. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Noguera-Gonzalez G, Jabbour E, Bose P, Kadia T, DiNardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, **Daver NG**. A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. *Am J Hematol* 93(2):277-285, 2/2018. e-Pub 11/2017. PMID: 29134664.
  138. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Noguera GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, **Daver N**, Estrov Z, Kadia T,

- Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. *Oncotarget* 9(11):9714-9727, 2/2018. e-Pub 1/2018. PMID: PMC5839396.
139. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, **Daver NG**, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. *Lancet Oncol* 19(2):240-248, 2/2018. e-Pub 1/2018. PMID: 29352703.
  140. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, **Daver NG**, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. *Am J Hematol* 93(3):401-407, 3/2018. e-Pub 12/2017. PMID: 29218851.
  141. Assi R, Kantarjian H, Ravandi F, **Daver NG**. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. *Curr Opin Hematol* 25(2):136-145, 3/2018. e-Pub 12/2017. PMID: 29206680.
  142. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, **Daver NG**, Cortes J, O'Brien S, Kantarjian H, Topp MS. Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression. *Am J Hematol* 93(3):371-374, 3/2018. e-Pub 12/2017. PMID: 29178361.
  143. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, **Daver NG**, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. *Cancer* 124(6):1160-1168, 3/2018. e-Pub 12/2017. PMID: PMC5851790.
  144. Masarova L, Alhurajji A, Bose P, **Daver NG**, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. *Eur J Haematol* 100(3):257-263, 3/2018. e-Pub 1/2018. PMID: PMC5814342.
  145. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, **Daver NG**, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma* 59(4):1-8, 4/2018. e-Pub 7/2017. PMID: PMC5773400.
  146. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, **Daver NG**. The emerging role of immune checkpoint based approaches in AML and MDS. *Leuk Lymphoma* 59(4):1-13, 4/2018. e-Pub 7/2017. PMID: PMC5872841.
  147. Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, **Daver NG**, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. *Leuk Lymphoma* 59(4):1-4, 4/2018. e-Pub 8/2017. PMID: 28838278.
  148. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, **Daver NG**, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. *Nat Rev Clin Oncol* 15(4):218, 4/2018. e-Pub 2/2018. PMID: 29434334.
  149. Chyla B, **Daver NG**, Doyle K, McKeegan E, Huang X, Ruvolo V, Wang Z, Chen K, Souers A, Levenson J, Potluri J, Boghaert E, Bhathena A, Konopleva M, Popovic R. Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia. *Am J Hematol*. e-Pub 5/2018. PMID: 29770480.

150. **Daver NG**, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. *Leukemia* 32(5):1094-1105, 5/2018. e-Pub 2/2018. PMID: 29487386.
151. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, **Daver NG**, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. *J Clin Oncol* 36(18):JCO2017776757, 6/2018. e-Pub 4/2018. PMCID: PMC6008108.
152. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, **Daver NG**, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Biol Blood Marrow Transplant* 24(6):1232-1236, 6/2018. e-Pub 9/2017. PMID: 28918304.
153. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, **Daver NG**, Kadia T, Ravandi F, Jain N, Alhurairi A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. *Leuk Lymphoma* 59(6):1-11, 6/2018. e-Pub 10/2017. PMCID: PMC6120342.
154. Boddu P, Oviedo SP, Rausch CR, Yam C, **Daver NG**, Kantarjian H, Kadia TM. PET-CT in AML-related hemophagocytic lymphohistiocytosis. *Leuk Lymphoma* 59(6):1-4, 6/2018. e-Pub 9/2017. PMID: 28958191.
155. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, **Daver NG**, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. *Cancer* 124(12):2534-2540, 6/2018. e-Pub 4/2018. PMID: 29645075.
156. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, **Daver NG**, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. *Nat Med* 24(7):1036-1046, 7/2018. e-Pub 6/2018. PMID: 29892070.
157. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, **Daver NG**, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. *Cancer* 124(13):2758-2765, 7/2018. e-Pub 4/2018. PMID: 29660836.
158. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, **Daver NG**. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. *Leuk Lymphoma* 59(7):1-5, 7/2018. e-Pub 11/2017. PMID: 29119847.
159. Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, **Daver NG**, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. *Biochim Biophys Acta Mol Cell Res* 1865(7):959-969, 7/2018. e-Pub 4/2018. PMCID: PMC5936474.
160. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, **Daver NG**, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory

- B-cell acute lymphoblastic leukaemia. *Br J Haematol* 182(3):442-444, 8/2018. e-Pub 6/2017. PMID: PMC6511975.
161. Lyle L, **Daver NG**. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. *Am J Manag Care* 24(16 Suppl):S356-S365, 8/2018. PMID: 30132679.
  162. Wiese M, **Daver NG**. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. *Am J Manag Care* 24(16 Suppl):S347-S355, 8/2018. PMID: 30132678.
  163. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, **Daver NG**, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. *Lancet Haematol* 5(9):e411-e421, 9/2018. e-Pub 8/2018. PMID: 30115541.
  164. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, **Daver NG**, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. *Leuk Lymphoma* 59(9):1-4, 9/2018. e-Pub 1/2018. PMID: 29338567.
  165. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, **Daver NG**, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML). *Am J Hematol* 93(9):1136-1141, 9/2018. e-Pub 8/2018. PMID: 30028037.
  166. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, **Daver NG**. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. *Blood* 132(16):1664-1674, 10/2018. e-Pub 9/2018. PMID: PMC6265645.
  167. Yalniz FF, **Daver NG**, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. *Clin Lymphoma Myeloma Leuk* 18(10):658-663.e2, 10/2018. e-Pub 6/2018. PMID: PMC6750214.
  168. Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, **Daver NG**, Andreeff M. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. *Haematologica* 103(10):1642-1653, 10/2018. e-Pub 5/2018. PMID: PMC6165819.
  169. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, **Daver NG**, Jabbour E, Burger J, Estrov Z, DiNardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. *Cancer* 124(21):4192-4201, 11/2018. e-Pub 10/2018. PMID: 30307606.
  170. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, **Daver NG**, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). *Blood* 132(19):2100-2103, 11/2018. e-Pub 9/2018. PMID: PMC6236463.
  171. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, **Daver NG**, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival. *Am J Hematol* 93(11):1376-1383, 11/2018. e-Pub 9/2018. PMID: 30117185.



172. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, **Daver NG**, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. *Leukemia* 32(11):2388-2398, 11/2018. e-Pub 4/2018. PMID: PMC6192870.
173. Jabbour E, Short NJ, Ravandi F, Huang X, **Daver NG**, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. *Lancet Haematol* 5(12):e618-e627, 12/2018. PMID: 30501869.
174. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, **Daver NG**, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk.* e-Pub 12/2018. PMID: 30635233.
175. Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, **Daver NG**. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. *Adv Exp Med Biol* 995:97-116, 2018. PMID: 30539507.
176. Oran B, **Daver NG**. Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword. *Biol Blood Marrow Transplant* 25(1):e1-e2, 1/2019. e-Pub 11/2018. PMID: 30500441.
177. Shroff GS, Truong MT, Carter BW, Benveniste MF, Kanagal-Shamanna R, Rauch G, Viswanathan C, Boddu PC, **Daver NG**, Wu CC. Leukemic Involvement in the Thorax. *Radiographics* 39(1):44-61, Jan-Feb, 1/2019. PMID: 30620703.
178. **Daver NG**. The Emerging Profile of Immunotherapy Approaches in the Treatment of AML. *Oncology (Williston Park)* 33(1):28-32, 1/2019. e-Pub 1/2019. PMID: 30731016.
179. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, **Daver NG**, Ohanian M, DiNardo C.D., Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. *Lancet Haematol* 6(1):e29-e37, 1/2019. e-Pub 12/2018. PMID: 30545576.
180. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, **Daver NG**, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. *J Hematol Oncol* 12(1):1, 1/2019. e-Pub 1/2019. PMID: PMC6318861.
181. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, **Daver NG**, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbnectin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. *Hematol Oncol* 37(1):96-102, 2/2019. e-Pub 12/2018. PMID: PMC6386594.
182. **Daver NG**, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. *Leukemia* 33(2):299-312, 2/2019. e-Pub 1/2019. PMID: PMC6365380.
183. **Daver NG**, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. *Cancer Discov* 9(3):370-383, 3/2019. e-Pub 11/2018. PMID: PMC6397669.
184. Angelova E, Audette C, Kovtun Y, **Daver NG**, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ,

- Khoury JD. CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. *Haematologica* 104(4):749-755, 4/2019. e-Pub 10/2018. PMID: PMC6442980.
185. Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, **Daver NG**, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. *Cancer* 125(7):1091-1100, 4/2019. e-Pub 12/2018. PMID: PMC6561101.
  186. Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, **Daver NG**, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Levenson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. *Haematologica*. e-Pub 5/2019. PMID: 31123034.
  187. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, **Daver NG**, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. *Blood Adv* 3(9):1533-1539, 5/2019. PMID: PMC6517659.
  188. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, **Daver NG**, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *Int J Hematol* 109(5):545-552, 5/2019. e-Pub 3/2019. PMID: 30830579.
  189. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, **Daver NG**, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. *Leuk Lymphoma*:1-9. e-Pub 5/2019. PMID: 31125272.
  190. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, **Daver NG**, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. *Cancer* 125(10):1665-1673, 5/2019. e-Pub 1/2019. PMID: 30668890.
  191. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, **Daver NG**. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. *Cancer* 125(9):1470-1481, 5/2019. e-Pub 11/2018. PMID: PMC6467779.
  192. **Daver NG**, Stein E. AML: The future is now or was it yesterday? *Best Pract Res Clin Haematol* 32(2):115, 6/2019. e-Pub 5/2019. PMID: 31203992.
  193. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, **Daver NG**, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. *Leuk Lymphoma*:1-4. e-Pub 6/2019. PMID: 31246142.
  194. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, **Daver NG**, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. *Leuk Lymphoma* 60(7):1-8, 7/2019. e-Pub 1/2019. PMID: PMC6594864.
  195. Yilmaz M, **Daver NG**. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. *Drugs* 79(11):1177-1186, 7/2019. e-Pub 6/2019. PMID: 31222627.
  196. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, **Daver NG**, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than

- Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. *Am J Hematol* 94(7):E188-E190, 7/2019. e-Pub 4/2019. PMCID: PMC6566858.
197. Medeiros BC, Chan SM, **Daver NG**, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. *Am J Hematol* 94(7):803-811, 7/2019. e-Pub 5/2019. PMCID: PMC6593671.
  198. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, **Daver NG**, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 125(15):2579-2586, 8/2019. e-Pub 4/2019. PMCID: PMC6625850.
  199. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, **Daver NG**. Emerging drug profile: CPX-351 (vyxeos) in AML. *Leuk Lymphoma*:1-10. e-Pub 9/2019. PMID: 31547736.
  200. Ravandi F, Assi R, **Daver NG**, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. *Lancet Haematol* 6(9):e480-e488, 9/2019. e-Pub 8/2019. PMCID: PMC6778960.
  201. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, **Daver NG**, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. *Am J Hematol* 94(9):984-991, 9/2019. e-Pub 6/2019. PMID: 31237017.
  202. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, **Daver NG**, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. *Cancer* 125(18):3219-3224, 9/2019. e-Pub 5/2019. PMID: 31150121.
  203. Ye MT, Wang Y, Wang SA, Pemmaraju N, **Daver NG**, Verstovsek S, Zhang Y, Zuo Z, Medeiros LJ, You MJ. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *Leuk Lymphoma*:1-4. e-Pub 11/2019. PMID: 31750750.
  204. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, **Daver NG**, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodocakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. *Lancet Oncol* 20(11):1544-1555, 11/2019. e-Pub 9/2019. PMID: 31563517.
  205. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, **Daver NG**, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. *Cancer* 125(21):3755-3766, 11/2019. e-Pub 7/2019. PMID: 31310323.
  206. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, **Daver NG**, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/Measurable Residual Disease at Transplantation. *Am J Hematol* 94(12):1382-1387, 12/2019. e-Pub 10/2019. PMID: 31595538.
  207. Short NJ, Kantarjian H, Ravandi F, **Daver NG**. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. *Ther Adv Hematol* 10:2040620719827310, 2019. e-Pub 2/2019. PMCID: PMC6378516.

208. Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, **Daver NG**. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. *Cancer Manag Res* 11:8817-8828, 2019. e-Pub 10/2019. PMID: PMC6782026.
209. Alfayez M, Ivan D, Pemmaraju N, **Daver NG**, DiNardo CD. Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia. *JCO Precis Oncol* 3, 2019. e-Pub 2/2019. PMID: 30957058.
210. Pankow JD, Richard-Carpentier G, **Daver NG**, Glass WF, Kala J. Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin. *CEN Case Rep*. e-Pub 1/2020. PMID: 31955389.
211. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, **Daver NG**, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. *Leukemia*. e-Pub 2/2020. PMID: 32099037.
212. Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, **Daver NG**. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. *Cancer Discov*. e-Pub 2/2020. PMID: 32014868.
213. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, **Daver NG**, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. *Blood Adv* 4(3):482-495, 2/2020. PMID: 32027746.
214. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, **Daver NG**, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation? *Blood* 135(6):449-452, 2/2020. e-Pub 12/2019. PMID: 31826244.
215. **Daver NG**. A bispecific approach to improving CAR T cells in AML. *Blood* 135(10):703-704, 3/2020. PMID: 32135017.
216. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, **Daver NG**, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. *Blood Adv* 4(8):1690-1699, 4/2020. PMID: 32330243.
217. Lachowiec CA, Loghavi S, Kadia TM, **Daver NG**, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. *Blood Adv* 4(7):1311-1320, 4/2020. PMID: 32251497.
218. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, **Daver NG**, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. *Blood Cancer J* 10(5):47, 5/2020. e-Pub 5/2020. PMID: 32366832.
219. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, **Daver NG**, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3-mutant acute myeloid leukemia. *Blood Cancer J* 10(5):48, 5/2020. e-Pub 5/2020. PMID: 32366841.
220. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, **Daver NG**. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are

- treated with checkpoint inhibitors. *Cancer* 126(10):2193-2205, 5/2020. e-Pub 3/2020. PMID: 32125707.
221. Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, **Daver NG**, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. *Clin Infect Dis* 71(1):63-71, 6/2020. e-Pub 8/2019. PMID: PMC7312220.
  222. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, **Daver NG**, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. *Am J Hematol* 95(6):612-622, 6/2020. e-Pub 3/2020. PMID: 32112433.
  223. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, **Daver NG**, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. e-Pub 6/2020. PMID: 32792304.
  224. Thakral B, **Daver NG**, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJ. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. *Leuk Lymphoma*:1-4. e-Pub 7/2020. PMID: 32696696.
  225. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, **Daver NG**, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. *Lancet Haematol* 7(7):e523-e533, 7/2020. PMID: 32589978.
  226. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, **Daver NG**, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. *Am J Hematol* 95(7):734-739, 7/2020. e-Pub 4/2020. PMID: 32170867.
  227. Masarova L, Bose P, Pemmaraju N, **Daver NG**, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. *Cancer*. e-Pub 7/2020. PMID: 32697338.
  228. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, **Daver NG**, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. *Leuk Lymphoma*:1-8. e-Pub 8/2020. PMID: 32755333.
  229. Saxena K, DiNardo C, **Daver NG**, Konopleva M. Harnessing Apoptosis in AML. *Clin Lymphoma Myeloma Leuk* 20 Suppl 1:S61-S64, 9/2020. PMID: 32862872.
  230. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, **Daver NG**. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. *Am J Hematol* 95(9):E225-E228, 9/2020. e-Pub 5/2020. PMID: 32356320.
  231. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, **Daver NG**, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Wierda WG, Wang SA,

- Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematol* 7(10):e724-e736, 10/2020. e-Pub 9/2020. PMID: PMC7549397.
232. Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, **Daver NG**, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. *Br J Haematol* 191(1):e10-e13, 10/2020. e-Pub 7/2020. PMID: 32686139.
233. **Daver NG**, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. *Blood Cancer J* 10(10):107, 10/2020. e-Pub 10/2020. PMID: 33127875.
234. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol* 13(1):132, 10/2020. e-Pub 10/2020. PMID: PMC7542942.
235. Lachowicz C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, **Daver NG**, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. *Am J Hematol* 95(11):E313-E315, 11/2020. e-Pub 9/2020. PMID: 32804409.
236. Konopleva M, Martinelli G, **Daver NG**, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J, Andreeff M. MDM2 inhibition: an important step forward in cancer therapy. *Leukemia* 34(11):2858-2874, 11/2020. e-Pub 7/2020. PMID: 32651541.
237. Chifotides HT, Masarova L, Alfayez M, **Daver NG**, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. *Blood Adv* 4(21):5336-5342, 11/2020. PMID: 33112940.
238. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, **Daver NG**, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. *Am J Hematol* 95(11):1296-1303, 11/2020. e-Pub 8/2020. PMID: 32697348.
239. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, **Daver NG**, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. *Am J Hematol* 95(11):1288-1295, 11/2020. e-Pub 8/2020. PMID: 32681739.
240. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, **Daver NG**, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. *Leukemia* 34(11):2914-2924, 11/2020. e-Pub 6/2020. PMID: 32546726.
241. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, **Daver NG**, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Adv* 4(22):5681-5689, 11/2020. PMID: 33211826.
242. Koshy AG, **Daver NG**, Fathi AT. A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition. *Best Pract Res Clin Haematol* 33(4):101220, 12/2020. e-Pub 11/2020. PMID: 33279176.

243. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, **Daver NG**, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). *Am J Hematol* 95(12):E326-E329, 12/2020. e-Pub 10/2020. PMID: 32886803.
244. Short NJ, Rafei H, **Daver NG**, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. *Blood Adv* 4(24):6117-6126, 12/2020. PMID: 33351107.
245. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, **Daver NG**. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. *Front Immunol* 11:590494, 2020. e-Pub 1/2021. PMID: PMC7859512.
246. Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, **Daver NG**. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. *Front Oncol* 10:588876, 2020. e-Pub 10/2020. PMID: PMC7606916.
247. **Daver NG**, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. *Front Oncol* 10:1538, 2020. e-Pub 8/2020. PMID: PMC7479234.
248. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, **Daver NG**, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. *Front Oncol* 10:582213, 2020. e-Pub 1/2021. PMID: PMC7878971.
249. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, **Daver NG**, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. *Acta Haematol* 143(6):1-7, 2020. e-Pub 4/2020. PMID: 32289808.
250. Samra B, Konopleva M, Isidori A, **Daver NG**, DiNardo C. Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. *Front Oncol* 10:562558, 2020. e-Pub 11/2020. PMID: PMC7675064.
251. Kantarjian H, Kadia T, DiNardo C, **Daver NG**, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. *Blood Cancer J* 11(2):41, 2/2021. e-Pub 2/2021. PMID: PMC7900255.
252. Venugopal S, **Daver NG**, Ravandi F. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. *Curr Hematol Malig Rep* 16(1):89-96, 2/2021. e-Pub 2/2021. PMID: 33630233.
253. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, **Daver NG**. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. *Cancer* 127(3):381-390, 2/2021. e-Pub 10/2020. PMID: 33119202.
254. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, **Daver NG**, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence

- of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. *Am J Hematol* 96(2):E50-E53, 2/2021. e-Pub 11/2020. PMID: 33156969.
255. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, **Daver NG**. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol* 14(1):34, 2/2021. e-Pub 2/2021. PMCID: PMC7901199.
  256. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, **Daver NG** Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. *J Immunother Cancer* 9(2), 2/2021. PMCID: PMC7919586.
  257. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, **Daver NG**, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The Leukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. *Am J Hematol* 96(2):241-250, 2/2021. e-Pub 12/2020. PMID: 33180322.
  258. Maiti A, DiNardo CD, **Daver NG**, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. *Blood Cancer J* 11(2):25, 2/2021. e-Pub 2/2021. PMCID: PMC7873265.
  259. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, **Daver NG**, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. *Blood Cancer J* 11(3):52, 3/2021. e-Pub 3/2021. PMCID: PMC7936977.
  260. Gao W, Wang L, Coffey JK, Wu H, **Daver NG**. Finite Element Modelling and Experimental Validation of Scratches on Textured Polymer Surfaces. *Polymers (Basel)* 13(7), 3/2021. e-Pub 3/2021. PMCID: PMC8036258.
  261. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, **Daver NG**, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. *Br J Haematol* 192(6):1054-1063, 3/2021. e-Pub 2/2021. PMID: 33618432.
  262. **Daver NG**. Immune checkpoint inhibitors in acute myeloid leukemia. *Best Pract Res Clin Haematol* 34(1):101247, 3/2021. e-Pub 1/2021. PMID: 33762102.
  263. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, **Daver NG**, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. *Blood Cancer J* 11(3):60, 3/2021. e-Pub 3/2021. PMCID: PMC7969746.
  264. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, **Daver NG**, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory



- acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. *Haematologica* 106(3):894-898, 3/2021. e-Pub 3/2021. PMID: PMC7927994.
265. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, **Daver NG**. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. *Blood Cancer Discov* 2(2):125-134, 3/2021. e-Pub 12/2020. PMID: PMC7935111.
  266. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, **Daver NG**, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. *Leukemia* 35(3):691-700, 3/2021. e-Pub 6/2020. PMID: 32561839.
  267. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, **Daver NG**, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. *Am J Hematol* 96(3):282-291, 3/2021. e-Pub 12/2020. PMID: PMC8128145.
  268. Achalare A, Dhawale A, Chaudhary K, Thorat T, Jain P, **Daver NG**. Delayed Treatment of a Traumatic Lumbosacral Dislocation With Associated Injuries: A Case Report. *JBJS Case Connect* 11(2), 4/2021. e-Pub 4/2021. PMID: 33979813.
  269. Lachowicz CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, **Daver NG**, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. *Blood Adv* 5(8):2173-2183, 4/2021. PMID: PMC8095152.
  270. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, **Daver NG**, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. *Blood Adv* 5(7):1876-1883, 4/2021. PMID: PMC8045494.
  271. Masarova L, DiNardo CD, Bose P, Pemmaraju N, **Daver NG**, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. *Blood Adv* 5(8):2156-2164, 4/2021. PMID: PMC8095138.
  272. Wei AH, **Daver NG**. Taking aim at IDH in fitter patients with AML. *Blood* 137(13):1706-1707, 4/2021. PMID: 33792680.
  273. **Daver NG**, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. *Am J Hematol* 96(5):E175-E179, 5/2021. e-Pub 3/2021. PMID: PMC8252033.
  274. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, **Daver NG**, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. *Leukemia* 35(5):1494-1499, 5/2021. e-Pub 4/2021. PMID: 33846541.
  275. Macchi R, **Daver NG**, Brenet M, Prat S, Hugheville L, Harmand S, Lewis J, Domalain M. Biomechanical demands of percussive techniques in the context of early stone toolmaking. *J R Soc Interface* 18(178):20201044, 5/2021. e-Pub 5/2021. PMID: PMC8150015.
  276. Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, **Daver NG**, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-

- Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. *Clin Lymphoma Myeloma Leuk* 21(5):338-344, 5/2021. e-Pub 1/2021. PMID: 33597098.
277. Masarova L, Bose P, Pemmaraju N, **Daver NG**, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. *Clin Lymphoma Myeloma Leuk* 21(5):318-327.e6, 5/2021. e-Pub 1/2021. PMID: 33551345.
278. Venugopal S, Maiti A, DiNardo CD, Loghavi S, **Daver NG**, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia. *Am J Hematol* 96(5):E154-E157, 5/2021. e-Pub 2/2021. PMID: PMC8237705.
279. **Daver NG**, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. *Blood Cancer J* 11(5):104, 5/2021. e-Pub 5/2021. PMID: PMC8159924.
280. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, **Daver NG**, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. *Clin Infect Dis* 72(10):1755-1763, 5/2021. e-Pub 4/2020. PMID: PMC8130026.
281. Fiskus W, Mill CP, Nabat B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, **Daver NG**, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GF11/KDM1A and BRD4 against AML and post-MPN secondary AML cells. *Blood Cancer J* 11(5):98, 5/2021. e-Pub 5/2021. PMID: PMC8138012.
282. Haddad F, **Daver NG**. Targeting CD47/SIRP $\alpha$  in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. *J Immunother Precis Oncol* 4(2):67-71, 5/2021. e-Pub 5/2021. PMID: PMC9153253.
283. Dhali K, Ghasemlou M, **Daver NG**, Cass P, Adhikari B. A review of nanocellulose as a new material towards environmental sustainability. *Sci Total Environ* 775:145871, 6/2021. e-Pub 2/2021. PMID: 33631573.
284. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, **Daver NG**, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. *Br J Haematol* 193(5):1004-1008, 6/2021. e-Pub 4/2021. PMID: 33821472.
285. Zeng Z, Ly C, **Daver NG**, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. *Ann Hematol* 100(6):1485-1496, 6/2021. e-Pub 3/2021. PMID: 33787984.
286. Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, **Daver NG**, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. *J Hematol Oncol* 14(1):94, 6/2021. e-Pub 6/2021. PMID: PMC8204504.
287. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, **Daver NG**, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. *Cancer* 127(12):2025-2038, 6/2021. e-Pub 3/2021. PMID: 33740268.
288. Abou Dalle I, Kantarjian HM, Ravandi F, **Daver NG**, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of

- lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. *Cancer* 127(11):1894-1900, 6/2021. e-Pub 1/2021. PMID: 33449377.
289. Short NJ, Konopleva M, Kadia T, Kebriaei P, **Daver NG**, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Am J Hematol* 96(7):E229-E232, 7/2021. e-Pub 4/2021. PMID: 33780038.
290. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, **Daver NG**, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). *Am J Hematol* 96(7):E246-E249, 7/2021. e-Pub 4/2021. PMID: 33811786.
291. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, **Daver NG**, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. *Cancer* 127(14):2489-2499, 7/2021. e-Pub 4/2021. PMID: 338249340.
292. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, **Daver NG**, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. *Haematologica* 106(7):1988-1990, 7/2021. e-Pub 7/2021. PMID: 338252931.
293. Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, **Daver NG**, Zha D, Konopleva M. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. *J Immunother Cancer* 9(7), 7/2021. PMID: 338323398.
294. **Daver N**, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. *Leukemia* 35(7):1843-1863, 7/2021. e-Pub 5/2021. PMID: 338257483.
295. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, **Daver N**, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. *Haematologica* 106(8):2121-2130, 8/2021. e-Pub 8/2021. PMID: 338327731.
296. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, **Daver NG**, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. *Blood Adv* 5(16):3163-3173, 8/2021. PMID: 338405193.
297. Yilmaz M, **Daver N**, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in CR1 improves outcomes in patients with newly diagnosed AML with very low FLT3 allelic burden. *Am J Hematol* 96(8):E275-E279, 8/2021. e-Pub 5/2021. PMID: 33891709.
298. Jain N, Maiti A, Ravandi F, Konopleva M, **Daver NG**, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. *Am J Hematol* 96(8):1000-1007, 8/2021. e-Pub 5/2021. PMID: 33991360.
299. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, **Daver NG**, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-

- Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. *Am J Hematol* 96(8):914-924, 8/2021. e-Pub 5/2021. PMID: 33901324.
300. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, **Daver NG**, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. *Cancer* 127(15):2641-2647, 8/2021. e-Pub 4/2021. PMID: 33823073.
  301. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, **Daver NG**, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. *Cancer* 127(15):2648-2656, 8/2021. e-Pub 4/2021. PMID: 33793964.
  302. Ghasemlou M, Le PH, **Daver NG**, Murdoch BJ, Ivanova EP, Adhikari B. Robust and Eco-Friendly Superhydrophobic Starch Nanohybrid Materials with Engineered Lotus Leaf Mimetic Multiscale Hierarchical Structures. *ACS Appl Mater Interfaces* 13(30):36558-36573, 8/2021. e-Pub 7/2021. PMID: 34284587.
  303. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, **Daver NG**, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. *Lancet Haematol* 8(8):e552-e561, 8/2021. PMID: 34329576.
  304. Wang J, Ma J, Cai C, **Daver NG**, Ning J. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules. *Stat Med* 40(21):4629-4639, 9/2021. e-Pub 6/2021. PMID: 34376777.
  305. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, **Daver NG**, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. *Cancer* 127(17):3113-3124, 9/2021. e-Pub 4/2021. PMID: 33914911.
  306. S Mehta R, Torres Cabala CA, DiNardo CD, **Daver NG**, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic M. Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. *Am J Hematol* 96(9):E350-E353, 9/2021. e-Pub 6/2021. PMID: 34096089.
  307. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, **Daver NG**, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. *Blood Cancer J* 11(9):162, 9/2021. e-Pub 9/2021. PMID: 34481264.
  308. DiNardo CD, Lachowicz CA, Takahashi K, Loghavi S, Xiao L, Kadia T, **Daver NG**, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. *J Clin Oncol* 39(25):2768-2778, 9/2021. e-Pub 5/2021. PMID: 34407653.
  309. Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, **Daver NG**. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. *Cancer* 127(20):3761-3771, 10/2021. e-Pub 6/2021. PMID: 34171128.

310. Pemmaraju N, Wilson NR, Khoury JD, Jain N, **Daver NG**, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. *Blood* 138(15):1373-1377, 10/2021. PMID: 34098573.
311. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, **Daver NG**, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. *Cancer* 127(19):3541-3551, 10/2021. e-Pub 6/2021. PMID: 34182597.
312. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, **Daver NG**, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. *Cancer* 127(20):3772-3781, 10/2021. e-Pub 7/2021. PMID: 34255353.
313. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, **Daver NG**, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. *Nat Commun* 12(1):6071, 10/2021. e-Pub 10/2021. PMCID: PMC8524723.
314. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, **Daver NG**, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. *Leukemia* 35(11):3282-3286, 11/2021. e-Pub 4/2021. PMCID: PMC8550958.
315. Wei SC, Mancuso JJ, **Daver NG**, Allison JP. Checkpoint Blockade + Chemotherapy: the Right Combination for AML? *Blood Cancer Discov* 2(6):551-554, 11/2021. e-Pub 9/2021. PMID: 35015675.
316. Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, **Daver NG**, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. *Blood* 138(18):1733-1739, 11/2021. PMCID: PMC8569418.
317. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, **Daver NG**, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. *Am J Hematol* 96(11):1420-1428, 11/2021. e-Pub 8/2021. PMID: 34351647.
318. Maiti A, **Daver NG**. Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia. *Clin Cancer Res* 27(21):5739-5741, 11/2021. e-Pub 9/2021. PMCID: PMC8563411.
319. Chien KS, Kim K, Noguerras-Gonzalez GM, Borthakur G, Naqvi K, **Daver NG**, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. *Br J Haematol* 195(3):378-387, 11/2021. e-Pub 8/2021. PMID: 34340254.
320. Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, **Daver NG**. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. *Blood Adv* 5(22):4569-4574, 11/2021. PMID: 34555853.
321. Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, **Daver NG**, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduiké RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva

- MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. *Cancer* 127(22):4213-4220, 11/2021. e-Pub 8/2021. PMID: PMC8556232.
322. Young PE, Kanagal-Shamanna R, Hu S, Tang G, Thakral B, **Daver NG**, Issa GC, Medeiros LJ, Konoplev S. Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution. *Leuk Res* 111:106685, 12/2021. e-Pub 8/2021. PMID: 34438119.
323. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, **Daver NG**, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. *Leuk Lymphoma* 62(14):1-9, 12/2021. e-Pub 8/2021. PMID: 34380367.
324. McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, **Daver NG**, Kadia TM, DiNardo C, Yi JS, Cuglievan B. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. *Blood Adv* 5(23):5215-5219, 12/2021. PMID: 34592761.
325. Kantarjian H, Short NJ, DiNardo C, Stein EM, **Daver NG**, Perl AE, Wang ES, Wei A, Tallman M. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. *Lancet Haematol* 8(12):e922-e933, 12/2021. e-Pub 10/2021. PMID: 34687602.
326. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, **Daver NG**, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. *Blood Adv* 5(23):5415-5419, 12/2021. PMID: 34525185.
327. Abou Dalle I, Kantarjian H, **Daver NG**, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. *Ann Hematol* 100(12):2957-2960, 12/2021. e-Pub 8/2021. PMID: 34350483.
328. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, **Daver NG**, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. *Leuk Lymphoma* 62(14):3501-3505, 12/2021. e-Pub 9/2021. PMID: 34474640.
329. Haddad F, **Daver NG**. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond! *Adv Exp Med Biol* 1342:273-295, 2021. PMID: 34972969.
330. Pasvolsky O, Daher M, Alatrash G, Marin D, **Daver NG**, Ravandi F, Rezvani K, Shpall E, Kebriaei P. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. *Front Oncol* 11:800110, 2021. e-Pub 1/2022. PMID: PMC8784883.
331. Abbas HA, Mohanty V, Wang R, Huang Y, Liang S, Wang F, Zhang J, Qiu Y, Hu CW, Qutub AA, Dail M, Bolen CR, **Daver NG**, Konopleva M, Futreal A, Chen K, Wang L, Kornblau SM. Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. *Front Oncol* 11:705627, 2021. e-Pub 8/2021. PMID: PMC8372368.
332. Isidori A, **Daver NG**, Curti A. Editorial: The Biological Landscape of Immunotherapy in AML. *Front Oncol* 11:671252, 2021. e-Pub 4/2021. PMID: PMC8081892.
333. Cerchione C, Romano A, **Daver NG**, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. *Front Oncol* 11:639387, 2021. e-Pub 3/2021. PMID: PMC8063727.
334. Isidori A, Cerchione C, **Daver NG**, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. *Front Oncol* 11:656218, 2021. e-Pub 5/2021. PMID: PMC8143531.
335. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, **Daver NG**, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. *Acta Haematol* 144(2):1-13, 2021. e-Pub 5/2020. PMID: PMC7270066.

336. Fiskus W, Boettcher S, **Daver NG**, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). *Blood Cancer J* 12(1):5, 1/2022. e-Pub 1/2022. PMID: PMC8752621.
337. Venugopal S, Takahashi K, **Daver NG**, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. *Blood Cancer J* 12(1):10, 1/2022. e-Pub 1/2022. PMID: PMC8789767.
338. Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, **Daver NG**, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. *Blood Cancer J* 12(1):23, 1/2022. e-Pub 1/2022. PMID: PMC8803998.
339. Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, **Daver NG**, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. *J Hematol Oncol* 15(1):12, 1/2022. e-Pub 1/2022. PMID: PMC8800349.
340. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, **Daver NG**, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. *Am J Hematol* 97(1):68-78, 1/2022. e-Pub 11/2021. PMID: 34716921.
341. Maiti A, Daver NG. A nonstick marrow may help to fry leukemia. *Blood* 139(8):1119-1121, 2/2022. PMID: 35201330.
342. Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer S, Alotaibi AS, Mohamed SF, Miller PG, Guber E, Weinstein S, Yacobovich J, Nikiforow S, Ebert BL, Lane A, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis M, Jordan MB. An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis. *Blood* 139(7):1098-1110, 2/2022. e-Pub 11/2021. PMID: PMC8854682.
343. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. *Blood* 139(6):907-921, 2/2022. e-Pub 10/2021. PMID: PMC8832475.
344. Zhou Y, Daver H, Trapkov B, Wu L, Wu M, Harpsøe K, Gentry PR, Liu K, Larionova M, Liu J, Chen N, Bräuner-Osborne H, Gloriam DE, Hua T, Liu ZJ. Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139. *Cell Res* 32(2):210-213, 2/2022. e-Pub 12/2021. PMID: PMC8807744.
345. Ghasemlou M, Mayes ELH, Murdoch BJ, Le PH, Dekiwadia C, Aburto-Medina A, Daver F, Ivanova EP, Adhikari B. Silicon-Doped Graphene Oxide Quantum Dots as Efficient Nanoconjugates for Multifunctional Nanocomposites. *ACS Appl Mater Interfaces* 14(5):7161-7174, 2/2022. e-Pub 1/2022. PMID: 35076220.
346. Venugopal S, Borthakur G, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva MY, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. *Blood Adv*. e-Pub 2/2022. PMID: 35201293.
347. Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. *Am J Hematol* 97(3):322-328, 3/2022. e-Pub 1/2022. PMID: 34981560.
348. Saxena K, DiNardo C, Daver N, Konopleva M. Harnessing Apoptosis in AML. *Clin Lymphoma Myeloma Leuk* 22(3):133-139, 3/2022. e-Pub 9/2021. PMID: 34602371.

349. Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. *Am J Hematol* 97(3):329-337, 3/2022. e-Pub 1/2022. PMID: PMC8884919.
350. Dhali K, Daver F, Cass P, Adhikari B. Surface modification of the cellulose nanocrystals through vinyl silane grafting. *Int J Biol Macromol* 200:397-408, 3/2022. e-Pub 1/2022. PMID: 35041891.
351. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. *Leuk Lymphoma* 63(3):1-4, 3/2022. e-Pub 10/2021. PMID: 34668451.
352. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. *Leuk Lymphoma*:1-10. e-Pub 4/2022. PMID: 35442137.
353. Ghasemlou M, Daver F, Murdoch BJ, Ball AS, Ivanova EP, Adhikari B. Biodegradation of novel bioplastics made of starch, polyhydroxyurethanes and cellulose nanocrystals in soil environment. *Sci Total Environ* 815:152684, 4/2022. e-Pub 1/2022. PMID: 34995611.
354. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. *Cancer* 128(8):1658-1665, 4/2022. e-Pub 1/2022. PMID: 35077575.
355. Tashakori M, Kadia TM, Loghavi S, Daver NG, Kanagal-Shamanna R, Pierce SR, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins C, Jabbour EJ, Medeiros LJ, Bhalla KN, Kantarjian HM, Ravandi F, Khoury JD. TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia. *Blood*. e-Pub 4/2022. PMID: 35390143.
356. Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. *Am J Hematol* 97(5):574-582, 5/2022. e-Pub 2/2022. PMID: PMC9303262.
357. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. *Blood Adv* 6(10):3027-3035, 5/2022. PMID: PMC9131912.
358. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. *Blood Cancer J* 12(5):77, 5/2022. e-Pub 5/2022. PMID: PMC9061716.
359. Spallone A, Alotaibi AS, Jiang Y, Daver N, Kontoyiannis DP. Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors. *Clin Lymphoma Myeloma Leuk* 22(5):305-310, 5/2022. e-Pub 10/2021. PMID: 34810120.
360. Lachowicz CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute



- myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. *Lancet Haematol* 9(5):e350-e360, 5/2022. PMID: 35483396.
361. Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver N, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. *Nat Med* 28(6):1212-1223, 6/2022. e-Pub 5/2022. PMID: 35618837.
  362. El Hussein S, Daver N, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. *Clin Lymphoma Myeloma Leuk* 22(6):e386-e391, 6/2022. e-Pub 12/2021. PMID: 34980577.
  363. Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. *Blood Cancer J* 12(6):91, 6/2022. e-Pub 6/2022. PMCID: PMC9184476.
  364. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. *J Hematol* 11(3):113-120, 6/2022. e-Pub 6/2022. PMCID: PMC9275440.
  365. Tashakori M, Wang W, Kadia TM, Daver NG, Montalban-Bravo G, Loghavi S, Wang SA, Medeiros LJ, Ravandi F, Khoury JD. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. *Leuk Res* 118:106860, 7/2022. e-Pub 5/2022. PMID: 35636055.
  366. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. *Blood Adv* 6(13):4006-4014, 7/2022. PMCID: PMC9278301.
  367. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. *Cancer* 128(14):2736-2745, 7/2022. e-Pub 4/2022. PMCID: PMC9232977.
  368. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. *Am J Hematol* 97(7):865-876, 7/2022. e-Pub 4/2022. PMID: 35384048.
  369. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. *Am J Hematol* 97(7):856-864, 7/2022. e-Pub 4/2022. PMID: 35357036.
  370. Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. *Am J Hematol* 97(7):885-894, 7/2022. e-Pub 4/2022. PMID: 35413152.
  371. Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. *Leuk Res* 119:106884, 8/2022. e-Pub 5/2022. PMID: 35691130.

372. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. *Am J Hematol* 97(8):1035-1043, 8/2022. e-Pub 5/2022. PMID: 35583199.
373. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. *Blood* 140(16):1753-1763, 10/2022. PMID: PMC9837415.
374. Yacoub A, Borate U, Rampal R, Ali H, Wang E, Gerds A, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh S, Schiller G, Assad A, Erickson-Viitanen S, Zhou F, Daver N. MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study. *Clin Lymphoma Myeloma Leuk* 22 Suppl 2:S324, 10/2022. PMID: 36163982.
375. Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. *Leukemia* 36(11):2729-2733, 11/2022. e-Pub 9/2022. PMID: PMC9613474.
376. Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. *Am J Hematol* 97(11):E408-E411, 11/2022. e-Pub 9/2022. PMID: 36054774.
377. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. *Am J Hematol* 97(11):1443-1452, 11/2022. e-Pub 9/2022. PMID: 36054614.
378. Daver N, Jonas BA, Medeiros BC, Patil U, Yan M. Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. *Leuk Lymphoma* 63(11):2711-2714, 11/2022. e-Pub 7/2022. PMID: 35834732.
379. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. *J Clin Oncol* 40(33):3848-3857, 11/2022. e-Pub 6/2022. PMID: PMC9671758.
380. Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. *Am J Hematol* 97(11):1427-1434, 11/2022. e-Pub 9/2022. PMID: 36053747.
381. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid

- Leukemia: Biology, Current Therapy, and Future Directions. *Cancer Discov* 12(11):2516-2529, 11/2022. PMID: PMC9627130.
382. Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. *Leuk Lymphoma* 63(13):3105-3116, 12/2022. e-Pub 9/2022. PMID: 36089905.
  383. Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, **Daver NG**, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. *Am J Hematol* 97(12):1560-1567, 12/2022. e-Pub 9/2022. PMID: 36087091.
  384. Maiti A, **Daver NG**. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions. *J Clin Oncol* 40(34):3994-3997, 12/2022. e-Pub 9/2022. PMID: PMC9746751.
  385. Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultonwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, **Daver NG**, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchoo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. *Leukemia* 36(12):2939-2946, 12/2022. e-Pub 10/2022. PMID: 36266326.
  386. Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahreni M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, **Daver NG**, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, D Code Team, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. *Cancers (Basel)* 15(1), 12/2022. e-Pub 12/2022. PMID: PMC9818576.
  387. Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, **Daver NG**, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. *Am J Hematol* 97(12):1599-1606, 12/2022. e-Pub 10/2022. PMID: 36117258.
  388. Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganon-Gomez I, Montalban-Bravo G, Chien KS, Do KA, **Daver NG**, Garcia-Manero G. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. *Leuk Lymphoma* 63(13):3154-3164, 12/2022. e-Pub 9/2022. PMID: 36059252.
  389. **Daver NG**, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. *J Clin Oncol* 40(35):4048-4059, 12/2022. e-Pub 7/2022. PMID: PMC9746764.
  390. Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, **Daver NG**, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. *Acta Haematol* 145(5):529-536, 2022. e-Pub 6/2022. PMID: 35717939.
  391. Senapati J, **Daver NG**, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. *Cancer J* 28(6):454-461, 2022 Nov-Dec 01, 2022. PMID: 36383908.
  392. Wurster S, Albert ND, Bharadwaj U, Kasembeli MM, Tarrand JJ, **Daver NG**, Kontoyiannis DP. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes

- and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. *Front Immunol* 13:838344, 2022. e-Pub 2/2022. PMID: PMC8896628.
393. Haddad F, Zeidan AM, **Daver NG**. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. *Cancer J* 28(1):43-50, 2022 Jan-Feb 01, 2022. PMID: 35072373.
394. Franklin S, Aitken SL, Shi Y, Sahasrabhojane PV, Robinson S, Peterson CB, **Daver NG**, Ajami NA, Kontoyiannis DP, Shelburne SA, Galloway-Peña J. Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. *Front Cell Infect Microbiol* 12:848580, 2022. e-Pub 3/2022. PMID: PMC9010033.
395. Siddiqui M, Konoplev S, Issa G, Kantarjian H, **Daver NG**, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic Features and Clinical Outcomes in Newly Diagnosed Myelodysplastic Syndrome with KMT2A rearrangements. *Am J Hematol*. e-Pub 1/2023. PMID: 36661399.
396. Yap TA, **Daver NG**, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. *Nat Med* 29(1):115-126, 1/2023. e-Pub 1/2023. PMID: 36658425.
397. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, **Daver NG**, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. *Lancet Haematol* 10(1):e24-e34, 1/2023. e-Pub 11/2022. PMID: 36402146.
398. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, **DDaver NG**, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. *Cancer*. e-Pub 1/2023. PMID: 36715486.
399. Shallis RM, **Daver NG**, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. *Cancer* 129(2):175-180, 1/2023. e-Pub 11/2022. PMID: 36397669.
400. Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, **Daver NG**, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. *Cancer* 129(4):560-568, 2/2023. e-Pub 12/2022. PMID: 36458426.
401. Morse JW, Rios M, Ye J, Rios A, Zhang CC, Daver NG, DiNardo CD, Zhang N, An Z. Antibody Therapies for the Treatment of Acute Myeloid Leukemia: Exploring Current and Emerging Therapeutic Targets. *Expert Opin Investig Drugs*. e-Pub 2/2023. PMID: 36762937.
402. Hasegawa K, Wei AH, Garcia-Manero G, **Daver NG**, Rajakumaraswamy N, Iqbal S, Chan RJ, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Sallman DA. Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. *Clin Lymphoma Myeloma Leuk* 23(2):127-137, 2/2023. e-Pub 11/2022. PMID: 36428152.
403. Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen DT, Buckstein RJ, Brunner AM, Carraway HE, **Daver NG**, Díez-Campelo M, de Witte TM, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner MC, Komrokji RS, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz GF, Scheinberg P, Stauder R, Van de Loosdrecht

- AA, Wei AH, Sekeres MA, Fenaux P. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. *Blood*. e-Pub 2/2023. PMID: 36724453.
404. Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, **Daver NG**, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. *Blood* 141(6):567-578, 2/2023. e-Pub 11/2022. PMID: 36399715.
405. Zeng Z, Maiti A, Herbrich S, Cai T, Cavazos A, Manzella T, Ma H, Hayes K, Matthews J, DiNardo CD, **Daver NG**, Konopleva MY. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. *Cancer* 129(4):531-540, 2/2023. e-Pub 12/2022. PMID: 36477735.
406. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, **Daver NG**, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). *Haematologica*. e-Pub 3/2023. PMID: 36951163.
407. Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, **Daver NG**. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. *Blood Adv* 7(6):933-942, 3/2023. e-Pub 11/2022. PMID: 36951163.
408. Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, **Daver NG**, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. *Am J Hematol* 98(3):E53-E56, 3/2023. e-Pub 12/2022. PMID: 36565294.
409. **Daver NG**, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Ramsingh G. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. *J Hematol Oncol* 16(1):19, 3/2023. e-Pub 3/2023. PMID: 369990239.
410. Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, **Daver NG**, Alvarado Y, Haddad FG, Pierce SR, Noguera Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. *Blood Adv*. e-Pub 3/2023. PMID: 36884300.
411. Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, **Daver NG**, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. *Blood Adv* 7(5):828-831, 3/2023. e-Pub 4/2022. PMID: 369996355.
412. **Daver NG**, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. *Blood* 141(11):1265-1276, 3/2023. e-Pub 10/2022. PMID: 36265087.
413. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, **Daver NG**, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C,

- Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. *Blood Adv* 7(10):1958-1966, 5/2023. e-Pub 10/2022. PMID: PMC10189379.
414. **Daver NG**, Iqbal S, Huang J, Renard C, Lin J, Pan Y, Williamson M, Ramsingh G. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. *Am J Hematol*. e-Pub 5/2023. PMID: 37139921.
415. Lee SE, Wang F, Greife M, Trujillo-Ocampo A, Ruiz-Vasquez W, Takahashi K, Abbas HA, Borges P, Antunes DA, Al-Atrash G, **Daver NG**, Molldrem JJ, Futreal A, Garcia-Manero G, Im JS. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. *Clin Cancer Res* 29(10):OF1-OF14, 5/2023. e-Pub 3/2023. PMID: PMC10192218.
416. Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, **Daver NG**, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. *Oncologist*. e-Pub 5/2023. PMID: 37156009.
417. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, **Daver NG**. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. *J Clin Oncol* 41(15):JCO2201794, 5/2023. e-Pub 3/2023. PMID: 36888930.
418. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, **Daver NG**, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. *JCO Precis Oncol* 7:e2200707, 5/2023. PMID: PMC10309573.
419. Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, **Daver NG**, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. *Cancer Immunol Res*. e-Pub 5/2023. PMID: 37163233.
420. Masarova L, Bose P, Pemmaraju N, **Daver NG**, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. *Cancer*. e-Pub 5/2023. PMID: 37243913.
421. Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, **Daver NG**, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. *Blood Cancer J* 13(1):101, 6/2023. e-Pub 6/2023. PMID: PMC10310786.
422. Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, **Daver NG**, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultonwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). *Blood Adv* 7(12):2709-2714, 6/2023. e-Pub 10/2022. PMID: 36260702.

423. Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, **Daver NG**, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. *Leukemia* 37(6):1336-1348, 6/2023. e-Pub 3/2023. PMID: PMC10244173.
424. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. *Cancer* 129(12):1856-1865, 6/2023. e-Pub 3/2023. PMID: 36892949.
425. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, **Daver NG**, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. *Am J Hematol*. e-Pub 6/2023. PMID: 37334870.
426. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, **Daver NG**, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. *Lancet Haematol* 10(6):e433-e444, 6/2023. e-Pub 5/2023. PMID: 37187201.
427. Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, **Daver NG**, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. *Cancer Immunol Res*:OF1-OF18. e-Pub 6/2023. PMID: 37285177.
428. DiNardo CD, Venugopal S, Lachowicz C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, **Daver NG** Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. *Blood Adv* 7(11):2378-2387, 6/2023. e-Pub 8/2022. PMID: PMC10220255.
429. Lachowicz CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, **Daver NG**, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. *Blood Cancer Discov* 4(4):276-293, 7/2023. PMID: 37102976.
430. Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultonwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, **Daver NG**, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). *Blood Rev* 60:101072, 7/2023. e-Pub 3/2023. PMID: 36934059.

#### Invited Articles

1. **Daver NG**, Cortes J. Molecular targeted therapy in Acute Myeloid Leukemia. *Hematology* 17 Suppl 1:S59-62, 4/2012. PMID: 22507781.

#### Editorials

N/A

#### Other Articles

1. **Daver NG**, Jabbour E. Salvage Treatment Options in AML. *Leukemia Insights* 16(2), 7/2011.
2. **Daver NG**. New therapeutic options in Adult ALL. *Leukemia Insights* 16(2), 9/2011.

#### Abstracts

1. **Daver NG**, Marina Kremyanskaya, Casey O'Connell, Kim-Hien Dao, Stephen T Oh, Aaron T. Gerds, Srdan Verstovsek, Sue Erickson-Viitanen, Feng Zhou, Albert Assad, and Abdurraheem Yacoub. A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3K $\delta$  Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis. *Blood* 132(353), <https://doi.org/10.1182/blood-2018-99-111338>, 2018.
2. **Daver NG**, Harry P. Erba, Nikolaos Papadantonakis, Daniel J. DeAngelo, Eunice S. Wang, Marina Y. Konopleva, Callum M. Sloss, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, and Hagop M. Kantarjian. A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies. *Blood* 132(27), 2018.
3. Mansour Alfayez, Hagop M. Kantarjian, Farhad Ravandi, Marina Y. Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia, Elias J. Jabbour, Gautam Borthakur, Courtney D. DiNardo, Zeev E. Estrov, Naveen Pemmaraju, Sherry A. Pierce, Musa E. Yilmaz, Nicholas J Short, Koichi Takahashi, Rita Assi, Michael Andreeff, Jorge E. Cortes, and **Daver NG**. Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. *Blood* 132(663), <https://doi.org/10.1182/blood-2018-99-117870>, 2018.
4. Betul Oran, Guillermo Garcia-Manero, Rima M. Saliba, Gheath Alatrash, Elias J. Jabbour, Uday Popat, Farhad Ravandi, Tapan M. Kadia, Jorge E. Cortes, Amin M. Alousi, Marina Y. Konopleva, Courtney D. DiNardo, Katy Rezvani, Mansour Alfayez, Elizabeth J. Shpall, Padmanee Sharma, Richard E Champlin, Hagop M. Kantarjian, and **Daver NG**. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. *Blood* 132(483), <https://doi.org/10.1182/blood-2018-99-115382>, 2018.
5. **Daver NG**, Guillermo Garcia-Manero, Sreyashi Basu, Jorge E. Cortes, Farhad Ravandi, Tapan M. Kadia, Marina Y. Konopleva, Elias J. Jabbour, Courtney D. DiNardo, Rita Assi, Sherry A. Pierce, Yesid Alvarado, Zeev E. Estrov, Naveen Pemmaraju, Koichi Takahashi, Jing Ning, Graciela M. Noguera González, Steven M. Kornblau, Mansour Alfayez, Jairo Matthews, Wilmer Flores, Jorge Blando, James P Allison, Padmanee Sharma, and Hagop M. Kantarjian. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. *Blood* 132(906), <https://doi.org/10.1182/blood-2018-99-120157>, 2018.
6. **Daver NG**, Daniel A Pollyea, Jacqueline S. Garcia, Brian A. Jonas, Karen W.L. Yee, Pierre Fenaux, Sarit Assouline, Norbert Vey, Rebecca Olin, Gail J. Roboz, Agostino Tafuri, Giuseppe Visani, Whitney Kirschbrown, Cherie Green, Connie Ma, Monique Dail, Jue Wang, Marion G Ott, Mehrdad Mobasher, Patrick Phuong, Wan-Jen Hong, Marina Y. Konopleva, and Michael Andreeff. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasana) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. *Blood* 132(767), <https://doi.org/10.1182/blood-2018-99-116013>, 2018.
7. Lucia Masarova, Srdan Verstovsek, Jorge E. Cortes, Naveen Pemmaraju, Prithviraj Bose, Maro N. Ohanian, Lingsha Zhou, Sherry A. Pierce, Romany Gergis, Gautam Borthakur, Zeev E. Estrov, Guillermo Garcia-Manero, Hagop M. Kantarjian, and **Daver NG**. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. *Blood* 132(352), <https://doi.org/10.1182/blood-2018-99-120251>, 2018.
8. Jain N, Jabbour EJ, Konopleva M, Pemmaraju N, Thompson PA, Short NJ, Kadia TM, Borthakur G, **Daver NG**, DiNardo CD, Aldoss I, Cook R, Ravandi F, Kantarjian H. A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult



- Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia. *Blood* 138(Supp. 1), 11/2021.
9. **Daver NG**, Aribi A., Montesinos P., Roboz G.J, Wang E.S, Walter R.B, Jeyakumar.D, DeAngelo D.J., Erba H.P, Advani A., Burke P.W, Martinelli G., Gastaud L., Thomas X., Altman J.K, Mendez L.M., de la Fuente A., Todisco E., Gaidano G., Curti A., Boissel N., Recher C., Schliemann C., Sloss C.M., Wang.J, Malcolm K.E, Zweidler-McKay P.A., Sweet K. A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMG632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.
  10. Vyas P, **Daver NG**, Chao M, Xing G, Renard C, Ramsingh G, Wei AH, Sallman DA. A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.
  11. **Daver NG**, Vyas P, Chao M, Xing G, Renard C, Ramsingh G, Sallman DA, Wei AH. A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53 -Mutant Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.
  12. Desikan SPP, Montalban-Bravo G, Ohanian M, **Daver NG**, Yilmaz M, Konopleva M, Kadia TM, Venugopal S, Schneider H, Chien KS, Kanagal-Shamanna R, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS). *Blood* 138(Supp. 1), 11/2021.
  13. Desikan SP, Kantarjian H, DiNardo CD, Borthakur G, **Daver NG**, Pemmaraju N, Alvarado Y, Burger JA, Linderman DB, Pierce SA, Ravandi F, Garcia-Manero G, Kadia TM. A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.
  14. Bazinet A, Jabbour EJ, Kantarjian H, Chien KS, DiNardo CD, Ohanian M, **Daver NG**, Kanagal-Shamanna R, Kadia TM, Takahashi K, Masarova L, Short NJ, Alvarado Y, Thompson PA, Montalban-Bravo G, Yilmaz M, Ravandi F, Kornblau SM, Pemmaraju N, Schneider H, Mirabella B, Naqvi K, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with 5-Azacitidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood* 138(Supp. 1), 11/2021.
  15. Venugopal S, Kantarjian H, Maiti A, Short NJ, Montalban-Bravo G, Alvarado Y, Chien KS, Kanagal-Shamanna R, Pemmaraju N, **Daver NG**, Kadia TM, Borthakur G, Jabbour EJ, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood* 138(Supp. 1), 11/2021.
  16. Venugopal S, Kantarjian H, Maiti A, Short NJ, Montalban-Bravo G, Alvarado Y, Chien KS, Kanagal-Shamanna R, Pemmaraju N, **Daver NG**, M. Kadia T, Borthakur G, Jabbour EJ, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood* 138(Supp. 1), 11/2021.
  17. Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour EJ, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Issa GC, Jain N, Ferrajoli A, Burger JA, Linderman DB, **Daver NG**, DiNardo CD, Konopleva M, Garcia-Manero G, Sasaki K, Ravandi F, Kadia TM. A Phase II Study of 5-Azacitidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. *Blood* 138(Supp. 1), 11/2021.
  18. Desikan SP, Ravandi F, Naveen Pemmaraju N, Konopleva M, Loghavi S, Borthakur G, Jabbour EJ, **Daver NG**, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Kwari M, Kantarjian H, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. *Blood* 138(Supp. 1), 11/2021.
  19. Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Borthakur G, Jabbour EJ, **Daver NG**, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Kwari M, Kantarjian H, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in

- Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. *Blood* 138(Supp. 1), 11/2021.
20. Haddad F, Kantarjian H, Short NJ, Konopleva M, Jain N, Ravandi F, **Daver NG**, Alvarado Y, Takahashi K, Garcia-Manero G, Velasquez M, Garris R, Jabbour EJ. A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. *Blood* 138(Supp. 1), 11/2021.
  21. Haddad F, Kantarjian H, Short NJ, Konopleva M, Jain N, Ravandi F, **Daver NG**, Alvarado Y, Takahashi K, Garcia-Manero G, Velasquez M, Garris R, Jabbour EJ. A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. *Blood* 138(Supp. 1), 11/2021.
  22. Kim K, Kantarjian H, Borthakur G, Takahashi K, Short NJ, DiNardo CD, Jabbour EJ, Chien KS, **Daver N**, Pemmaraju N, Jain N, Adewale L, Montalban-Bravo G, Wierda WG, Verstovsek S, Konopleva M, Ravandi F, Kadia TM. A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood* 138(Supp. 1), 11/2021.
  23. Pemmaraju N, Marconi G, Todisco E, Montesinos P, Lane AA, Sweet K, Wang ES, Deconinck E, Rizzieri DA, Walter RB, Aribi A, Lebon D, Levy MY, Mazzarella L, Martinelli G, Gigli G, Erba HP, Acuña-Cruz E, Konopleva M, Kantarjian H, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PA, DeAngelo DJ, **Daver NG**. A Study of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). *Blood* 138(Supp. 1), 11/2021.
  24. Pemmaraju N, Marconi G, Todisco E, Montesinos P, Lane AA, Sweet K, Wang ES, Deconinck E, Rizzieri DA, Walter RB, Aribi A, Lebon D, Levy MY, Mazzarella L, Martinelli G, Gigli F, Erba HP, Acuña-Cruz E, Konopleva M, Kantarjian H, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PAZ, DeAngelo DJ, **Daver NG**. A Study of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). *Blood* 138(Supp. 1), 11/2021.
  25. Short NJ, DiNardo CD, **Daver NG**, Nguyen D, Yilmaz M, Kadia TM, Garcia-Manero G, Issa GC, Huang X, Qiao W, Sasaki K, Montalban-Bravo G, Chien KS, Borthakur G, Delumpa R, Milton A, Pierce SA, Jabbour EJ, Konopleva M, Kantarjian H, Ravandi F. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. *Blood* 138(Supp. 1), 11/2021.
  26. Kadia TM, Pemmaraju N, Yilmaz M, **Daver NG**, Li L, Lyu M, Huang M, Zeng K, Cook R, Parmar S, Mukherjee S, Sadeghi T, DiNardo CD, Issa GC, Jabbour EJ, Borthakur G, Jain N, Verstovsek S. Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes. *Blood* 138(Supp. 1), 11/2021.
  27. Short NJ, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour EJ, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo CD, **Daver NG**, Issa GC, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien KS, Ravandi F, Kadia TM, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce SA, Waller L, Banks G, Kantarjian H, Cortes JE. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. *Blood* 138(Supp. 1), 11/2021.
  28. Mohamed SF, Abuasba T, Chien KS, Montalban-Bravo G, Darbaniyan F, Pierce SA, Soltysiak KA, Haddad F, DMcCall D, Cuglievan B, Jabbour EJ, **Daver NG**, Kadia TM, Pemmaraju N, Kantarjian H, Garcia-Manero G. Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis. *Blood* 138(Supp. 1), 11/2021.
  29. Mohamed SF, Assi R, Ning J, Xiao L, Jabbour EJ, Pemmaraju N, Kadia TM, Jain N, DiNardo CD, Yilmaz M, Maiti A, Issa GC, Short NJ, Bose P, Masarova L, Garcia-Manero G, Ravandi F, Konopleva M, Kantarjian H, **Daver N**. Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. *Blood* 138(Supp. 1), 11/2021.
  30. Hammond D, Kadia TM, DiNardo CD, Konopleva M, Short NJ, **Daver NG**, Ravandi F, Pemmaraju N, Jabbour EJ, Chien KS, Pierce SA, Kantarjian H, Garcia-Manero G,

- Montalban-Bravo G. Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. *Blood* 138(Supp. 1), 11/2021.
31. Davis JA, Fiskus WC, **Daver N**, Mill CP, Birdwell C, Salazar A, Philip K, Kadia TM, DiNardo CD, Leoni M, Burrows F, Bhalla KN. Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models. *Blood* 138(Supp. 1), 11/2021.
  32. Skwarska A, Moujalled DM, Panis PF, Patel S, Zhang Q, Herbrich S, Kurvilla V, Baran N, Pomilio G, Halilovic E, Mistry P, Ruvolo V, Ruvolo PP, Derréal A, Banquet S, Niemira M, Kretowski A, **Daver NG**, Andreeff M, Wei AH, Konopleva M. Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo. *Blood* 138(Supp. 1), 11/2021.
  33. Jia Y, Zhang Q, Weng C, Ramage CL, Nishida Y, Chao M, Maute RL, Herbrich S, Zhang W, Andreeff M, **Daver NG**, Konopleva M. Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models. *Blood* 138(Supp. 1), 11/2021.
  34. Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann L, Montoya RH, Muftuoglu M, Ruvolo V, Mak PY, Tao W, Carter BZ, Kojima K, **Daver NG**, Lesegetrain A, Seki T, Shacham S, Konopleva M, Andreeff M. Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML. *Blood* 138(Supp. 1), 11/2021.
  35. Maiti A, DiNardo CD, **Daver NG**, Kadia TM, Borthakur G, Short NJ, Pemmaraju N, Ohanian M, Alvarado Y, Takahashi K, Pierce SA, Patel KP, Jabbour EJ, Garcia-Manero G, Ravandi F, Kantarjian H, Konopleva M. Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. *Blood* 138(Supp. 1), 11/2021.
  36. Pemmaraju N, Martinelli G, Todisco E, Lane AA, Acuña-Cruz E, Deconinck E, Wang ES, Sweet K, Rizzieri DA, Marconi G, Mazzarella L, DeAngelo DJ, Montesinos P, Gigli F, Erba HP, Konopleva M, Kantarjian H, Walter RB, Aribi A, Lebon D, Levy MY, Sloss CM, Malcolm KE, Zweidler-McKay PA, **Daver NG**. Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). *Blood* 138(Supp. 1), 11/2021.
  37. **Daver NG**, Lee KH, Jung CW, Yoon SS, Arellano ML, Yoon J, Lee N, Kim H, Lee J, Jonas BA, Baek S. First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML). *Blood* 138(Supp. 1), 11/2021.
  38. Rivera D, Kadia TM, Montalban-Bravo G, Faderl S, Sasaki K, Short NJ, **Daver NG**, DiNardo CD, Masarova L, Ferrajoli A, Jabbour EJ, Borthakur G, Al Azzawi H, Konopleva M, Garcia-Manero G, Andreeff M, Kantarjian H, Ravandi F, Alvarado Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). *Blood* 138(Supp. 1), 11/2021.
  39. Curtis Lachowicz C, DiNardo CD, Morita K, Furudate K, Wang F, Tanaka T, Wang SA, Kadia TM, **Daver NG**, Short NJ, Khoury JD, Patel K, Medeiros LJ, Konopleva M, Ravandi F, Takahashi K, Loghavi S. Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. *Blood* 138(Supp. 1), 11/2021.
  40. Lachowicz C, DiNardo CD, Morita K, Furudate K, Wang F, Tanaka T, Wang SA, Kadia TM, **Daver NG**, Short NJ, Khoury JD, Patel K, Medeiros LJ, Konopleva M, Ravandi F, Takahashi K, Loghavi S. Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. *Blood* 138(Supp. 1), 11/2021.
  41. Haddad F, Kantarjian H, Short NJ, Sasaki K, Ravandi F, Kebriaei P, Huang X, Jain N, Konopleva M, Garcia-Manero G, Champlin RE, Kadia TM, Takahashi K, **Daver NG**, Khoury JD, Jorgensen JL, Wang SA, Jacob J, Garris R, O'Brien SM, Jabbour EJ. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or

- without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. *Blood* 138(Supp. 1), 11/2021.
42. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, **Daver NG**, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. *Blood* 138(Supp. 1), 11/2021.
  43. Venugopal S, Issa GC, Konopleva M, DiNardo CD, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SA, Takahashi K, Tang G, Loghavi S, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian H, **Daver NG**. NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). *Blood* 138(Supp. 1), 11/2021.
  44. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, **Daver NG**, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SA, Villarreal J, Qazilbash MH, Konopleva M, Kantarjian H. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. *Blood* 138(Supp. 1), 11/2021.
  45. Venugopal S, Chien KS, Hammond D, Kanagal-Shamanna R, Sasaki K, Kadia TM, DiNardo CD, Konopleva M, **Daver N**, Ravandi F, Pemmaraju N, Short NJ, Issa GC, Takahashi K, Estrov ZE, Pierce SA, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. *Blood* 138(Supp. 1), 11/2021.
  46. Pemmaraju N, Bhalla KN, **Daver NG**, Wilson NR, Fiskus WC, Ravandi F, Garcia-Manero G, Kadia TM, DiNardo CD, Jabbour EJ, Burger JA, Short NJ, Alvarado Y, Jain N, Masarova L, Verstovsek S, Issa GC, Qiao W, Khoury JD, Pierce SA, Miller D, Konopleva M, Kantarjian H, Borthakur G. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood* 138(Supp. 1), 11/2021.
  47. **Daver NG**, Affinito J, Cai H, Dobrowolska H, Dow E, Eguchi K, Song G, Stoudemire J, Watanbe A, Komarnitsky P. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia ( MLL )-Rearrangement or Nucleophosmin 1 ( NPM1 ) Mutation. *Blood* 138(Supp. 1), 11/2021.
  48. **Daver NG**, Affinito J, Cai H, Dobrowolska H, Dow E, Eguchi K, Song G, Stoudemire J, Watanbe A, Komarnitsky P. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia ( MLL )-Rearrangement or Nucleophosmin 1 ( NPM1 ) Mutation. *Blood* 138(Supp. 1), 11/2021.
  49. **Daver NG**, Konopleva M, Maiti A, Kadia TM, DiNardo CD, Loghavi S, Pemmaraju N, Jabbour E, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Golez M, Pierce SA, González GMN, Ning J, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. *Blood* 138(Supp. 1), 11/2021.
  50. **Daver N**, Konopleva M, Maiti A, Kadia TM, DiNardo CD, Loghavi S, Pemmaraju N, Jabbour EJ, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Golez M, Pierce SA, González GMN, Ning J, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. *Blood* 138(Supp. 1), 11/2021.
  51. Abuasab T, Kantarjian H, Garcia-Manero G, Montalban-Bravo G, Alvarado Y, Yilmaz M, Pemmaraju N, Chien KS, Mohamed SF, **Daver NG**, Kornblau SM, Burger JA, Jain N, Islam R, Courtney D, DiNardo CD, Borthakur G, Ravandi F, Kadia TM. Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML). *Blood* 138(Supp. 1), 11/2021.

52. Venugopal S, Jabbour EJ, Pemmaraju N, Montalban-Bravo G, Chien KS, **Daver NG**, Jain J, Burger JA, Alvarado Y, Maiti A, DiNardo CD, Borthakur G, Malla R, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. *Blood* 138(Supp. 1), 11/2021.
53. Venugopal S, Jabbour EJ, Pemmaraju N, Montalban-Bravo G, Chien KS, **Daver NG**, Jain N, Burger JA, Alvarado Y, Maiti A, DiNardo CD, Borthakur G, Malla R, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. *Blood* 138(Supp. 1), 11/2021.
54. Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, DiNardo CD, Sasaki K, **Daver N**, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Bhalla KN, Jabbour EJ, Ferrajoli A, Takahashi K, Rausch CR, Malla R, Marek K, Brandt M, Popat UR, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood* 138(Supp. 1), 11/2021.
55. Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, DiNardo CD, Sasaki K, **Daver NG**, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Bhalla KN, Jabbour EJ, Ferrajoli A, Takahashi K, Rausch CR, Malla M, Marek K, Brandt M, Popat UR, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood* 138(Supp. 1), 11/2021.
56. Becker MN, Howson A, Quill TA, **Daver NG**, Stein EM. Practice Gaps and Barriers in Optimal Care Among Healthcare Providers Treating Patients with Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Results of a Two-Phase Qualitative/Quantitative Study. *Blood* 138(Supp. 1), 11/2021.
57. Fiskus WC, Mill CP, Birdwell C, Davis JA, Salazar A, Philip K, Kadia TM, DiNardo CD, Takahashi K, McGeehan GM, **Daver NG**, Bhalla KN. Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models. *Blood* 138(Supp. 1), 11/2021.
58. Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, **Daver NG**. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. *Blood* 138(Supp. 1), 11/2021.
59. Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, **Daver NG**. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. *Blood* 138(Supp. 1), 11/2021.
60. **Daver NG** Aribi A, Montesinos P, Roboz GJ, Wang ES, Walter RB, Jeyakumar D, DeAngelo DJ, Erba HP, Advani A, Burke PW, Martinelli G, Gastaud L, Thomas X, Altman JK, Mendez LM, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Konopleva M, Sallman DA, Torres L, Marcucci G, Kantarjian H, Sloss CM, Malcolm KE, Zweidler-McKay PA, Sweet K. Safety and Efficacy from a Phase 1b/2 Study of IMG632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.
61. **Daver NG**, Aribi A, Montesinos P, Roboz GJ, Wang ES, Walter RB, Jeyakumar D, DeAngelo DJ, Erba HP, Advani A, Burke PW, Martinelli G, Gastaud L, Thomas X, Altman JK, Mendez LM, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C,

- Konopleva M, Sallman DA, Torres L, Marcucci G, Kantarjian H, Sloss CM, Malcolm KE, Zweidler-McKay PA, Sweet K. Safety and Efficacy from a Phase 1b/2 Study of IMG632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.
62. Muftuoglu M, Li L, Basyal M, Liang S, Ball CJ, Chen K, Kumar P, Lesegretain A, **Daver NG**, Andreeff M. Single-Cell Proteomics Identifies Leukemia Landscape Associated with Clinical Outcomes in R/R AML Treated with MDM2i (Milademetan) and FLT3i (Quizartinib): Putative Role of CD68 and Diversity Index. *Blood* 138(Supp. 1), 11/2021.
  63. Chang KH, Basyal M, Alaniz Z, Honma D, Tsutsumi S, Dos Santos CE, **Daver NG**, Andreeff M. Targeting EZH1/2 to Restore Chemosensitivity in Dormant Myeloid Leukemia Stem Cells. *Blood* 138(Supp. 1), 11/2021.
  64. Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, **Daver NG**, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour EJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch J, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. *Blood* 138(Supp. 1), 11/2021.
  65. Short NJ, Kantarjian H, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, **Daver NG**, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju NP, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob J, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Jabbour EJ. Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. *Blood* 138(Supp. 1), 11/2021.
  66. Lachowicz C, DiNardo CD, Takahashi K, Loghavi S, Xiao LC, Kadia TM, **Daver NG**, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban-Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau SM, Ravandi F, Jabbour EJ, Konopleva M, Kantarjian H. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.
  67. Trabal A, Gibson A, McCall D, Mahadeo KM, Toepfer L, Roth ME, Buzbee M, Kadia TM, Garces S, Konopleva M, DiNardo CD, **Daver NG**, Short NJ, Issa GC, Ravandi F, Nunez C, Khazal SJ, Paek H, Brackett J, Garcia-Manero G, Kantarjian H, Marcogliese AN, Dreyer Z, Redell MS, Yi JS, Stevens AM, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration. *Blood* 138(Supp. 1), 11/2021.
  68. **Daver NG**, Perl AE, Maly J, Levis M, Ritchie E, Litzow MR, McCloskey J, Smith CC, Schiller GJ, Bradley T, Tiu RV, Naqvi K, Dail M, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia. *Blood* 138(Supp. 1), 11/2021.

#### Book Chapters

1. **Daver NG**, Udden M. Acute Lymphoblastic Leukemia. In: Hematology Oncology. In Press.

#### Books (edited and written)

N/A

#### Letters to the Editor

N/A

#### Manuals, Teaching Aids, Other Teaching Publications

N/A

#### Other Publications

1. Online. Tapan Kadia, Farhad Ravandi, Naval Daver, Gautam Borthakur, Jorge E Cortes, Elias Jabbour, Steven M Kornblau, Srdan Verstovsek, William Wierda, Jan A Burger, Zeev Estrov, Courtney DiNardo, Xiao Qin Dong, Naveen Pemmaraju, Maro Ohanian, Koichi

- Takahashi, Stephany Hendrickson, Hagop Kantarjian, Guillermo Garcia-Manero Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia. Blood (ASH Annual Meeting) 126(23)
2. Online. Lorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, ELias Jabbour, Farhad Ravandi, Guillermo Garcia-Manero, Zeev Estrov, Tapan Kadia, Naveen Pemmaraju, Alessandra Ferrajoli, Naval Daver, Sara Emogene Dellasala, Sherry Pierce, Srdan Verstovsek, Jorge E. Cortes. Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)? Blood (ASH Annual Meeting) 126(5158), 12/2015
  3. Online. Lucia Masarova, Naval Daver, Naveen Pemmaraju, Prithviraj Bose, Sherry Pierce, Jorge E Cortes, Hagop M Kantarjian, Srdan Verstovsek. Does Occurrence of Other Malignancy after Essential Thrombocythemia and Polycythemia Vera Influence Their Rate of Transformation to Myelofibrosis? Blood (ASH Annual Meeting) 126(5189), 12/2015
  4. Online. Ghayas C Issa, Hagop M Kantarjian, C Cameron Yin, Koji Sasaki, Guillermo Garcia-Manero, Courtney DiNardo, Koichi Takahashi, Farhad Ravandi, Jorge E Cortes, Naval Daver, Tapan Kadia, Srdan Verstovsek, Sherry Pierce, Elias Jabbour. Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. Blood (ASH Annual Meeting) 126(4874), 12/2015

#### **EDITORIAL AND REVIEW ACTIVITIES**

##### **Editor/Service on Editorial Board(s)**

N/A

##### **Member of Editorial Review Board**

N/A

##### **Journal Reviewer**

N/A

##### **Other Editorial and Review Activities**

N/A

#### **TEACHING**

##### **Teaching Within Current Institution -**

##### **Formal Teaching**

##### **Courses Taught**

N/A

##### **Training Programs**

Instructor, Grand Rounds  
2016

Instructor, Grand Rounds

##### **Other Formal Teaching**

Instructor, Secondary Hemophagocytic Lymphohistiocytosis in Adults: Identification and management paradigms, Course Hours: 1  
1/2016-present

Instructor, Immune checkpoint and vaccines in AML, Course Hours: 1  
7/2016-present

##### **Supervisory Teaching**

##### **Committees**

##### **Advisory Committees**

N/A

##### **Supervisory Committees**

N/A

##### **Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

Instructor, PPS Coordinator for II Year Medical Students, Baylor College of Medicine  
7/2008-12/2008

Instructor, IPS Coordinator for II Year Medical Students, Baylor College of Medicine  
6/2009-present

**Training Programs**

Instructor, Grand Rounds, Los Angeles  
2015

Instructor, Grand Rounds, Cleveland  
2015

Instructor, Grand Rounds, Nashville  
2015

Instructor, Grand Rounds, Maryland  
2015

Grand Rounds, New Jersey  
2015

Instructor, Grand Rounds, Washington, DC  
2015

Instructor, Grand Rounds, Wichita  
2016

Instructor, Grand Rounds, Maryland  
2016

Instructor, Grand Rounds, Wyoming  
2016

Instructor, Grand Rounds, New Jersey  
2016

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**



N/A

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

N/A

**Presentations at National or International Conferences**

**Invited**

N/A, India Association of Hematology, Mumbai, India, 2013

N/A, European Hematology Association, Vienna, Austria, 2015

N/A, European Hematology Association, Copenhagen, Denmark, 2016

Molecular and/or immune therapies in AML/MDS, Mumbai Hematology Group, Mumbai, India, 1/2017

**Other, Including Scientific Exhibitions**

N/A

**Seminar Invitations from Other Institutions**

N/A

**Lectureships and Visiting Professorships**

N/A

**Other Presentations at State and Local Conferences**

n/a, American College of Physicians, San Diego, CA, 2011

n/a, American Society of Hematology, San Francisco, CA, 2014

N/A, American Society of Hematology, New Orleans, LA, 2015

n/a, National Conference of Leukemia Epigenetics, Atlanta, GA, 2016

N/A, Twenty-Eighth International Association for Comparative Research on Leukemia and Related Diseases Symposium, Houston, TX, 2016

Presenter, Society of Hematologic Oncology, Houston, TX, 2016

Session Chair, Society of Hematologic Oncology, Houston, TX, 2016

Update on checkpoint clinical trials in AML, Hematology Malignancies PO1 Meeting, Houston, TX, 10/2016

MDS/MPN, MPN Practitioner Conference, MPN Advisory Forum, Incyte Corporation, Brooklyn, NY, 11/2016

Next checkpoints: A Look at future immunotherapeutic drug development in hematologic malignancies, Chemotherapy Symposium, New York, NY, 11/2016

Lone Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory AML Patients Treated with SGI-110 in Phase 2 Studies, American Society of Hematology, San Diego, CA, 12/2016

Phase IB/II Study of Nivolumab in Combination with AZA in Patients with Relapsed AML, American Society of Hematology, San Diego, CA, 12/2016

Ruxolitinib in Combination with 5-Azacytidine as therapy for Patients with Myelofibrosis, American Society of Hematology, San Diego, CA, 12/2016

Checkpoint Inhibitors in Hematologic Malignancies, XXVII IACRLRD Symposium, Houston, TX, 10/3/2017

## **PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

### **Professional Society Activities, with Offices Held**

#### **National and International**

American Society of Clinical Oncology, TX  
Member, 7/2008-present

American Society of Hematology  
Member, 7/2008-present

SWOG Committee Member  
Member, 6/2013-present

European Hematology Association  
Member, 2014-present

European Society of Medical Oncology  
Member, 2014-present

Society of Immunotherapy  
Member, 2015-present

#### **Local/State**

CME Advisory Committee, Houston, TX  
Member, 7/2018-present

Society of Hematologic Oncology, Houston, TX  
Member, 5/2020-present

## **UNIQUE ACTIVITIES**

1. Member of Baylor College of Medicine Intercollegiate Jeopardy Team 2006-2007 & 2007-2008
2. Residency Assistance Program (RAP) Group Leader 2007-2008
3. Buddy Committee (Residents Activity Committee) – Baylor College of Medicine 2006-2008
4. American College of Physicians 2005,2006,2007,2008,2009
5. Grant Medical College Students Association (GMCSA) – Class President 2001

6. Grant Medical College Students Association (GMCSA) – Magazine Secretary 2003

**DATE OF LAST CV UPDATE**

4/20/2023